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Background:  The proportion of nosocomial Staphylococcus infections caused by 
methicillin-resistant Staphylococcus aureus (MRSA) has increased from 22% in 1995 to 
63% in 2004. Blood stream infections, more commonly referred to as bacteremias, 
represented the majority (75.5%) of hospital-onset MRSA cases. The economic impact of 
Staphylococcus aureus bacteremia merits investigation. 
 
xii 
 
Methods:  This was a retrospective cohort analysis within Cerner HealthFacts data 
warehouse. Eligible patients were those who had Staphylococcus aureus bacteremia and 
were discharged between January 1, 2000, and December 31, 2006.    Inclusion criteria 
include age > 18 years old and onset of infection > 48 hours post admission.  The crude 
association was measured by subtracting the total mean hospital charge for MSSA 
bacteremia from the MRSA charge.  A generalized linear model using a gamma 
distribution and log link were used to determine the adjusted hospital charge and post-
infection length of stay for the MRSA and MSSA groups.  Path analysis was used to 
describe the relationships between infection susceptibility status, LOS and total hospital 
charge.   
 
Results:  During the study period, 930 patients meet all the inclusion and exclusion 
criteria.  The overall total hospital charge was $111,636 (MRSA = $121,713, MSSA = 
$97,307.)  The crude difference in mean charge was $24,406.  The multivariable model 
included predicted a MRSA patient would have an increased total charge of $22,889.  
MRSA had a higher total charge but when patients were more severely ill, MRSA 
charges decreased while MSSA charges increased. The second multivariable model 
predicted a MRSA patient would have an increased post-infection LOS of 1.3 days. 
However, the magnitude of increased post-infection LOS based on pre-infection LOS 
was different for MRSA and MSSA patients.  The path analysis model indicated the 
direct and indirect effects of susceptibility status on both post-infection LOS and total 
charge were relatively small.  
xiii 
 
 
Conclusion:  This investigation was the first large multi-center investigation to examine 
the economic impact of MRSA and MSSA bacteremia.  MRSA was associated with a 
higher total charge and longer post-infection LOS than MSSA patients.  The path analysis 
model analyzed suggests the actually role of infection susceptibility status on post-
infection LOS and total charge was minor. 
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CHAPTER 1  
Introduction 
 
Overview of the document 
 This dissertation describes a study designed to examine the relationship between 
Staphylococcus aureus bacteremia susceptibility status (methicillin resistant or 
susceptible) and hospital charges.  This chapter provides background information 
necessary to understand the significance of the project.  The second chapter 
systematically reviews the available literature and provides more extensive background 
on previous investigations, economic issues, confounding factors, propensity scores and 
path analysis.  Chapter 3 discusses the preliminary investigation. Chapter 4 describes the 
methodology used for the dissertation project.  The results are provided in Chapter 5, 
followed by a discussion and concluding remarks in Chapter 6.  
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Background 
Ever since the discovery of antibiotics, resistance has been emerging.  
Antimicrobial resistance is an important public health issue.  In 1999, the Centers for 
Disease Control and Prevention (CDC) and several other national agencies developed an 
Interagency Task Force dedicated to antimicrobial resistance.  Each year since its 
inception, the Antimicrobial Task Force has published an Annual Report describing the 
current state of resistance in the US.[1]  According to the CDC, the proportion of total 
nosocomial Staphylococcus species infections caused by methicillin-resistant 
Staphylococcus aureus (MRSA) has increased from 22% in 1995 to 63% in 2004. [2]  
Additionally, a recent investigation sought to describe the incidence and distribution of 
invasive MRSA in nine communities across the United States.[3] The results showed 
blood stream infections, more commonly referred to as bacteremias, represented the 
majority of hospital-onset MRSA cases (75.5%).   
The scientific community and healthcare professionals have acknowledged the 
importance of understanding the economic impact of resistance.  The “cost of resistance” 
has been defined as “the incremental cost of care for an infection due to a resistant isolate 
minus the care costs of infection with a susceptible strain of the same organism.”[4]  For 
this analysis, the “cost of resistance” can be approximated by subtracting the total 
hospital charges of the susceptible from the resistant groups.  The difference in charges 
estimates the “cost of resistance.”  
Performing and/or interpreting an economic analysis requires further explanation.  
For example, the terms costs and charges must be defined.  Some authors have used the 
3 
 
terms interchangeably, but this is incorrect.  Costs and charges reflect different economic 
values.  Specifically, charges always over-inflate cost. [5]  For the purposes of this report, 
great care has been given to use the terms costs and charges appropriately.  Previous 
investigations have used costs or charges as outcomes depending on study design and 
data availability.  The economic background section provides a more thorough discussion 
of costs versus charges. 
Any epidemiologic investigation attempting to describe the relationship between 
an exposure and outcome must consider potential confounders.  Confounding factors are 
variables that (1) are associated with the outcome as well as the exposure, and (2) are not 
variables in the causal pathway.  If confounding exists, an association may appear to be 
present when one does not exist or there may seem to be no association when a true 
association does exist.[6] Therefore, it is imperative to identify confounders and control 
for them.  In most situations confounders are identified a priori based on previous 
investigations or expert knowledge.[7]  For this investigation, underlying severity of 
illness and comorbid conditions were identified as confounders. [8]  Additionally, 
hospital level factors (e.g. teaching status, bed size, geographic location) can also 
confound the relationship between susceptibility status and total charges. 
Propensity scores are another way to control for confounding.  Observational 
studies employ this method to eliminate bias from an unequal distribution of confounders 
thereby mimicking the purpose of randomization in a randomized, controlled clinical 
trial.  Propensity scores are the probability of exposure given measured baseline 
variables.[9]  This probability can then be used as a matching or stratification factor, as a 
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covariate in multivariable model or to perform inverse probability of exposure 
weighting.[10]  
The relationship between susceptibility status and charge is further complicated 
by length of stay (LOS).  LOS must be considered in two parts as it relates to the onset of 
a nosocomial infection.  The pre-infection LOS refers to the number of days in the 
hospital before infection onset.  The post-infection LOS refers to hospital stay after the 
infection onset.  Post-infection LOS is an intermediary between susceptibility status and 
charges. Pre-infection LOS is related to infection susceptibility, post-infection LOS and 
total charge.  Therefore, pre-infection LOS can be considered as confounding the 
relationship between infection susceptibility status and charges.  A technique called path 
analysis can be used to provide estimates of the magnitude and significance of 
hypothesized relationships between variables when some of the variables lie in the 
proposed causal pathway.      
Previously, single center investigations have suggested that MRSA bacteremia 
may  increase hospitalization costs by 1.2- to 2-fold over methicillin-susceptible 
Staphylococcus aureus (MSSA) bacteremia.[11-15]  This supports the hypothesis that 
MRSA bacteremia is associated with higher costs than MSSA bacteremia. However, one 
study performed in three German hospitals indicated that hospital costs between patients 
with MRSA and MSSA patients with blood stream infections were similar.[16]   A large 
multi-center investigation may help to quantify the economic impact of MRSA vs. MSSA 
bacteremia.   
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Objectives 
The current investigation has four primary objectives which are listed below. 
 
1. Measure the crude difference in total hospital charges between methicillin-resistant 
Staphylococcus aureus (MRSA) vs. methicillin-susceptible Staphylococcus aureus 
(MSSA) bacteremia.   
 
2. Determine the impact of methicillin resistance vs. methicillin susceptibility in 
Staphylococcus aureus bacteremia (SAB) on total hospital charges while adjusting for 
potential confounders. 
 
3. Determine the impact of methicillin resistance vs. methicillin susceptibility in SAB on 
post-infection length of stay (LOS) while adjusting for potential confounders. 
 
4. Describe the relationships between SAB methicillin susceptibility, LOS and total 
hospital charges. 
 
Significance  
As described above, the incidence of MRSA is increasing and the majority of 
hospital acquired MRSA infections are bacteremias.[3]  These factors stimulate the need 
for further investigation into the relationship between MRSA and MSSA bacteremia.    
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Before a clinician prescribes a drug, the potential risks and benefits must be 
considered.  The benefit of prescribing an antibiotic often outweighs the adverse 
consequences for an individual patient since the side effect profile of most antibiotics is 
reasonably mild.  However, with each antibiotic administration antimicrobial resistance is 
a potential unintended consequence.  By identifying any unintended financial 
consequences, strategies for minimizing the costs and thereby resistance can be more 
fervently pursued. For example, infection control strategies are expensive but they may 
seem more manageable if the “cost of resistance” is significantly more.  Finding ways to 
minimize resistance through an economic approach will positively impact public health. 
The scientific community and healthcare professionals recognize the importance 
of understanding the economic impact of resistance.[4]  Understanding the financial 
implications associated with MRSA will better equip hospitals to manage their financial 
resources.   
Also, the relationship between infection susceptibility status with respect to LOS 
and total hospital charges needs to be more appropriately defined.  It is common 
knowledge that LOS greatly contributes to hospital charges.  But the relationship between 
pre- and post-infection LOS, infection susceptibility status and charges has not been fully 
characterized.  Previous investigations have explored charges/costs and LOS as 
independent outcomes.  Path analysis will be used to characterize the relationship 
between infection susceptibility status, LOS and total charge. 
Data from over forty hospitals will be considered making this a large multi-center 
investigation.  This includes both academic teaching medical centers and community 
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hospitals.  Previous investigations only explored the economic impact of SAB in teaching 
hospitals.  A multi-center investigation will provide a larger sample size than previous 
single center reports. This investigation will have greater external validity than previous 
studies.     
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CHAPTER 2 
Literature Review 
 
MRSA Bacteremia Overview 
Staphylococcus aureus is a significant cause of infectious disease in humans.  
More specifically, it is an important cause of bloodstream infections. MRSA accounts for 
more than half of all S. aureus infections in many institutions.  MRSA rates have been 
reported as high as 70% in Intensive Care Units (ICUs).[17] These are serious infections 
with mortality rates ranging from 15 to 60%.[13, 14, 18-22]  MSSA infections can also 
be fatal.  A meta-analysis estimated the mortality rate of MSSA bacteremia to be 
12%.[23]  
Why do some patients have MRSA versus MSSA infections?  The investigators at 
the Mayo Clinic list 4 risk factors for an MRSA infection (1) a current or recent 
hospitalization, (2) residing in a long term care facility, (3) invasive devices, and (4) 
recent antibiotic use with fluoroquinolones (ciprofloxacin, ofloxacin or levofloxacin) or 
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cephalosporins.[24]  Published reports have expounded on these 4 risk factors by 
subdividing the categories into areas of greater risk.  For example, in an investigation 
published by McHugh et al.[13], factors including cardiac surgery during hospitalization 
and venous or bladder catheter > 3 days during hospitalization were identified to increase 
the risk of MRSA over MSSA.  However, both infections caused by MSSA or MRSA are 
a serious public health concern meriting additional attention. 
 
Economic Analysis of MRSA Bacteremia Overview 
Several authors have identified key factors to consider when estimating the cost of 
resistance.  Within the context of these publications, the considerations discussed were 
within a theoretical framework.  Each author discussed how an investigation into the 
“cost of resistance” should be designed.  A compilation of these considerations is 
summarized below in Table 2.1.  McGowan was the first to distinguish the various 
viewpoints which determine applicable costs.[25] Such perspectives include the 
physician, the patient, the healthcare business, the drug industry and society.  Ultimately, 
the societal/public health perspective would reflect the most comprehensive economic 
impact of resistance.  This viewpoint would consider resistance from the perspective of 
the social good.  Defining the economic burden of resistance quickly becomes 
complicated when forced to consider the long-term implications of antimicrobial usage.  
For example, treating a patient’s infection with an antibiotic may expedite that patient’s 
recovery, which would decrease short-term expenses.  But antibiotic usage indirectly 
increases resistance thus increasing the overall cost of resistance to society despite the 
10 
 
individual patient’s short-term savings.  It is less complicated to define the economic 
burden of resistance from the hospital perspective.  This perspective only considers 
expenditures that directly impact the hospital.  Defining the perspective is an essential 
first step in any economic analysis as it determines what “costs” will be considered. [26]  
11 
 
Table 2.1  Key factors to consider in estimating the cost of resistance 
 
Cosgrove 
& 
Carmeli 
[27] 
Howard 
et al [4] 
McGowan 
[25] 
Patient Characteristics     
   Severity of underlying illness  X  
   Mortality X X  
   Morbidity X   
      Length of stay (LOS) X X  
      Intensive care unit (ICU) admission X   
      Need for surgery/other procedures X   
      Status at discharge (functional) X   
Economic Considerations X   
   Hospital cost (fixed and marginal) X   
      Per day per bed by specialty  X  
      Per day per bed ICU vs. general vs. other  X  
      Antimicrobial acquisition costs  X  
      Antimicrobial administration costs  X X 
      Staff time increase (MD / nurse)  X  
      Occurrence of other procedures  X  
      Occurrence of other infections/complications  X  
      Lab costs (screening and diagnosis)  X X 
      Infection control staff   X X 
      Treatment failure   X 
   Hospital charges (larger than costs) X   
   Resources utilized X   
      Supplies, housekeeping, waste disposal, etc.  X X 
Hospital Factors     
   Infection Control Practices   X 
   Formularies/Protocols   X 
   Educational Programs   X 
The “x” represents factors identified in each paper as important considerations.   
 LOS = length of stay 
 ICU = intensive care unit 
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The choice of control group was very important.  One of the pioneer studies 
examining SAB compared resistant infections to both susceptible patients and to patients 
without blood stream infections.[14]  Although uninfected hospitalized patients represent 
the true source population, this comparison assesses the burden of having a resistant 
infection rather than no infection. Comparing a resistant to a susceptible infection is 
appropriate when trying to determine the excess economic burden attributable to the 
resistant infection.[27] The rest of the investigations discussed used a susceptible control 
group. 
 
Economic Background 
Understanding costs, charges and reimbursements from a hospital’s perspective is 
complex.  In a strictly economic sense, a cost can be thought of as “the extra amount of 
resource consumption incurred for providing a service as compared to the costs of not 
providing that service.” [5]  In layman’s terms, costs refer to the price a hospital pays for 
the resources it consumes.  This is different than a charge, which is simply a list price that 
hospitals charge to their customers. [5]  Charges are always higher than the actual 
hospital cost so that patients who can pay will cover the losses from those who cannot 
afford to pay. [5]  
Hospital reimbursements are an entirely different level of complexity.  The 
government, through Medicare and Medicaid, is the major payer of hospital services in 
the United States.  In 1982, Medicare moved to a prospective payment system (PPS) for 
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hospital reimbursement to control costs by capping the allowable reimbursement.[28]  A 
hospital’s listed charge, therefore, is not the same as the insurance reimbursement.   
PPS works by dividing admissions into diagnosis-related group (DRG) categories.  
A DRG is computed taking into account the affected organ system, up to nine ICD-9-CM 
diagnosis codes, up to 6 ICD-9-CM procedure codes, morbidity and gender.  Each DRG 
has an associated DRG relative weight.  DRG relative weights reflect the average level of 
resources a Medicare patient in a particular DRG will utilize.  The weight can range from 
greater than 0 to less than 20.  An average hospital stay would have weight of 1. 
Conditions with greater costs are assigned a higher DRG relative weight. Hospitals are 
then reimbursed a fixed rate depending on the relative weight of the DRG.  
Reimbursements are also adjusted for geographic differences in wage, hospital teaching 
status, proportion of low income individuals a hospital treats and cost outliers.[29]   
Since charges are known to inflate the economic burden of hospitalization, cost-
to-charge ratios have been used to better approximate actual cost from charges [11]; 
however, cost-to-charge ratios are a poor approximation of actual costs.[30] Additionally, 
cost-to-charge ratios are specific for a particular hospital.  The identity of a hospital must 
be known to determine which cost-to-charge ratio is appropriate.  Cost-to-charge ratios 
were not used in this analysis since the identity of each hospital was unknown. 
As previously mentioned, hospital charges are considered to be a gross 
overestimation of the true hospitalization cost.  But the difference between MRSA and 
MSSA bacteremia for charge and cost has been shown to be similar.[31]  Although this 
observation has been noted in the literature, mathematics would suggest that a 50% 
14 
 
overestimation in charge would correspond to a 50% overestimation in the difference 
between charges.  Therefore, it will be more useful to discuss differences as percent 
increase or relative change. 
Descriptive statistics for variables that are non-normally distributed are 
conventionally expressed as median and interquartile range.  Charges/costs are rarely 
normally distributed.  It would seem logical to express the central tendency of charge/cost 
as a median, but averages are used since economists are interested solely in means.[32] 
This convention stemmed from the practical need to obtain annual budget data which 
could be obtained by multiplying the arithmetic mean (average) by the total number of 
patients.  Therefore, means are the central tendency measures reported for charge/cost 
data.[33] 
 
Confounding Factors  
Confounding factors are variables that are associated with the outcome as well as 
the exposure.  However, they cannot be variables in the causal pathway (i.e., 
intermediary) between the exposure and outcome.  A directed acyclic graph (or a causal 
diagram) depicting the relationship between exposure, outcome and confounder can be 
found below in Figure 2.1.  
 
  
15 
 
Figure 2.1. Mechanism of confounding 
 
 
If confounding exists, an association may appear to be present when one does not 
exist or there may seem to be no association when a true association does exist.[6]  This 
is because the confounder distorts the effect of exposure on outcome.  It is important to 
identify and control for confounding since it can lead to a misinterpretation of study 
results.   
Confounders should be identified from the base population, not the study sample.  
This means that confounders are identified a priori based on previous investigations or 
expert knowledge.[7]  Since almost all investigations examine a small subset of a larger 
population, it is possible that a confounding effect within the population may not be 
present within the sample.  Known confounders should be included regardless of their 
“statistical significance” in the sample.  
Once confounders are identified they must be controlled.  This can be done during 
the design phase through restriction, matching or randomization or during analysis via 
stratification-, or multivariable analysis.[34]  By definition, randomization should 
equalize the distribution of all known and unknown confounders between the groups.  
Confounder 
Outcome Exposure 
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The technique is frequently used in prospective, experimental study designs.  However, 
the retrospective nature of database projects does not allow for this technique.  
Retrospective investigations more commonly use restriction or matching.  Restriction 
involves limiting the scope of design to one stratum of the confounder but, this limits the 
investigation’s external validity.  Matching is used to make the groups comparable with 
respect to the confounder.  This technique requires more complicated analysis since the 
matched nature of the data must be taken into consideration.  Additionally,  “over-
matching” can become a concern if the groups become too similar as to disguise as actual 
effect.[35]   
As stated above, confounding can be controlled for at the analysis level through 
stratification or multivariable analysis.  When confounding exists, the magnitude of effect 
will be the same between the strata but the crude estimate of effect of the exposure and 
outcome will be different.[36]  Stratification quantifies the relationship between exposure 
and outcome as a pooled estimate with respect to the confounder.  Stratification becomes 
more complicated when multiple confounders exist because the statistical power to detect 
a difference decreases as the number of observations within a stratum decreases.  
Mathematical modeling during the analysis can account for many confounders 
simultaneously.  Randomization, restriction, matching, stratification, and multivariable 
analysis are all methods for reducing confounding.  Except for randomization, each 
technique requires the confounder to be identified and cannot control any unmeasured 
confounding effects.[37]  
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Several variables have been acknowledged as known confounders in the literature 
regarding the relationship between infection susceptibility and charge.  Specifically, 
underlying severity of illness and comorbid conditions have been identified.[38]   
Underlying severity of illness and comorbid conditions are both gauges of baseline health 
status not actual disease acuity.  There is an important distinction between underlying 
severity of illness and severity of illness during the infection. Severity of illness during 
the infection is considered an intermediary, not a confounder since a sicker patient would 
require a longer length of stay and would increase total charges.  
There is currently no universally recognized severity of illness score for infectious 
disease outcomes.[27] Recently, a comorbidity risk-adjustment measure was developed 
for MRSA infections.[39]  The Chronic Disease Score (CDS) was modified to include 
more co-morbidities to create a CDS-MRSA.  Similar to the original CDS, patient 
medications were used to identify the co-morbidities.  This method has not yet been well 
validated and it requires a complete medication history.  Confounding attributable to co-
morbid conditions has been most commonly estimated using the Acute Physiology and 
Chronic Health Evaluation (APACHE) score [40, 41], McCabe/Jackson score [42] and 
the Charlson Comorbidity score.[43] The APACHE score is intended for use with ICU 
patients and requires clinical parameters not generally available in administrative 
databases.[40, 41]  The McCabe/Jackson score has been evaluated for non-ICU patients 
and has been used for patients with gram-negative infections.  MRSA is a gram- positive 
organism.[42]  The Charlson Comorbidity Index was designed to measure the 1-year 
mortality risk in a general population of hospitalized patients.[43]  It has been modified 
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to use multiple International Classification of Disease, Ninth Revision, Clinical 
Modification (ICD-9-CM) diagnosis codes to determine the score.[44]  DRG categories 
have also been used as a surrogate for severity of illness.[45]  Although not well 
validated, DRGs have been used as a surrogate for severity of underlying illness in 
MRSA bacteremia.[13]  DRGs were originally developed to accurately assess the cost of 
hospitalization by accounting for severity of illness relative to other DRG classifications. 
[46, 47]  A more complete discussion of DRGs can be found in the economic background 
section.   
Data from a meta-analysis demonstrated a significant increase in mortality 
associated with MRSA bacteremia relative to MSSA bacteremia.[20]  Mortality is most 
typically reported as discharged alive or expired.  Differences in mortality are especially 
important in an economic analysis since patients who die during their hospitalization 
have truncated costs.   
Length of stay (LOS) is known to increase hospital charges; however, LOS must 
be considered in 2 parts as it relates to the onset of a nosocomial infection.  The pre-
infection LOS refers to the number of hospital days before infection onset.  The post-
infection LOS refers to days after the infection onset.  The relationship between infection 
susceptibility status and total hospital charges is complicated by LOS.  Post-infection 
LOS is an intermediary between susceptibility status and charges.  As discussed above, it 
should not be included as a confounder in a model measuring the association between 
total susceptibility and charges.  Pre-infection LOS is related to infection susceptibility, 
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post-infection LOS and total charges.  Therefore, pre-infection LOS can be considered as 
confounding the relationship between infection susceptibility status and charge.      
Hospital level factors can also confound the relationship between susceptibility 
status and total charges. As previously mentioned, DRG payments are calculated by 
adjusting for hospital specific factors.  Income wage index, hospital teaching status, and 
percentage of low income patients are also confounders to be considered.   These factors 
are confounders since they directly impact hospital charges and are related to 
susceptibility status.   
 
Previous Investigations 
As previously mentioned, there have been prior investigations attempting to 
quantify the economic burden of MRSA bacteremia. They suggest MRSA bacteremia 
increases hospitalization costs by 1.2-to 2-fold over MSSA bacteremia.[11-15]  Table 2.2 
below outlines investigations that examined MRSA vs. MSSA bacteremia.  Only one of 
the investigations used hospital charge as an outcome variable.[11]  This investigation 
also reported costs as calculated using Medicare cost-to-charge ratios.  The estimated 
difference in median charge attributable to MRSA vs. MSSA was 1.36 fold greater (1.44 
for median attributable cost).  Regarding the different estimates in hospitalization costs 
between investigations, it has been hypothesized that the differences are due to disparities 
in study populations and differences in calculating costs.[27] With the exception of one 
investigation [16], all previous reports support the hypothesis that infections caused by 
MRSA are associated with higher costs compared to MSSA infections. 
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Table 2.2. Investigations comparing the economic impact of MRSA vs. MSSA bacteremia 
 
Author Setting Sample Size Data Source Economic variable 
Outcome 
Measures Result Notes 
Abramson 
MA., et al. 
[14] 
University 
tertiary 
care 
center 
 
8 MRSA 
11 MSSA 
19 Controls 
 
Pairwise-
matched case 
control study 
Total & variable 
direct costs of 
hospitalization 
• LOS 
• Cost 
•  Attributable median 
LOS: 12 vs. 4 days 
(MRSA vs. MSSA) 
•  Attributable median 
total costs: $27,083 vs. 
$9,661 (MRSA vs. 
MSSA) 
MRSA and MSA 
groups 
compared to 
non-infected 
controls, not 
each other. 
Cosgrove, 
S.E., et al. 
[11] 
University 
tertiary 
care 
center 
 
348  
(96=MRSA) 
Cohort study Hospital 
charges were 
used to 
approximate 
costs using the 
Medicare cost-
to-charge ratio 
• LOS  
• Hospital 
charges 
• MRSA had a median 
attributable LOS of 2 
days  
• MRSA had a median 
attributable hospital 
charge of $6,916 
($3,836 median 
attributable hospital 
cost) 
Charges 
reported were 
post-infection 
only. 
Greiner 
W, et al. 
[16] 
3 
University 
teaching 
centers in 
Germany 
 
ESRD on 
hemodialy
sis 
109 Retrospective 
cohort study 
Hospital costs 
attributable to 
bacteremia and 
costs of other 
bacteremia 
related medical 
services after 
discharge. 
• Mortality 
• Cost 
• No difference in 
duration of stay, 
outcome or mortality 
between the groups. 
Investigation 
examined 
community-
acquired and 
nosocomial 
infections 
separately. 
 
Largest 
component of 
total costs was 
the initial 
hospitalization 
(93%). 
(continued)
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Table 2.2 (continued) 
Author Setting Sample Size Data Source Economic variable 
Outcome 
Measures Result Notes 
Lodise, 
T.P., et 
al. 
[12] 
University 
tertiary care 
center 
 
353 (174 
hospital 
onset) 
Retrospectiv
e cohort 
study 
Microcosting 
structure: 
fixed indirect 
costs, 
variable 
direct costs, 
& fixed 
direct costs 
• LOS 
• Costs 
•  Adjusted mean LOS: 
19.1 vs. 14.2 days 
(MRSA vs. MSSA)  
• Adjusted mean hospital 
cost: $21,577 vs. 
$11,688 (MRSA vs. 
MSSA)  
Included both 
hospital and 
community 
onset SAB.  
Adjusted model 
did include a 
variable for 
hospital-
acquired SAB. 
McHugh, 
C.G., et 
al. 
[13] 
Tertiary-care 
hospital  
60 
(20=MRSA, 
42=MSSA) 
Retrospectiv
e case-
control study
All hospital 
costs 
accrued by 
the patient 
during 
hospitalizati
on 
• Cost • Cost per day for MRSA 
($5,878) vs. for MSSA 
($2,073) 
Used CMI for 
severity of 
illness. 
Reed 
SD., et 
al. 
[15] 
105 hospital 
patients 
 
ESRD on 
hemodialysis 
143 
(54=MRSA, 
89=MSSA) 
Prospective 
cohort study 
Hospital 
costs for 
index 
hospitalizati
on and for 
rehospitaliza
tion 
• Cost 
• Costs at 
12 wks   
• Initial hospitalization 
costs: $21,251 vs. 
$13,978 (MRSA vs. 
MSSA)  
• 12 week costs: $25,518 
vs. $17,354 (MRSA vs. 
MSSA)   
Used 
propensity 
scores in 
multivariable 
regression. 
MRSA = methicillin-resistant Staphylococcus aureus 
MSSA = methicillin-susceptible Staphylococcus aureus 
LOS =  length of stay 
ESRD = end stage renal disease 
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There have been several single center investigations that have quantified the costs 
of MSSA-SAB and MRSA-SAB.[11-15, 31, 48-52]  Each report is briefly summarized 
below.  The first two investigation presented [11, 12] are the most similar to the current 
study. 
Cosgrove et al. [11] examined mortality, length of stay and hospital charges as 
outcome variables using a cohort design.  They concluded that median attributable 
hospital charge for infection caused by MRSA bloodstream infections was $6,916 per 
patient.  Costs were also estimated using hospital charges adjusted by the Medicare cost-
to-charge ratio from onset of infection until discharge.  There was no significant 
difference in mortality between the resistant and susceptible groups, but there was an 
increased median attributable length of stay for MRSA of two days.  This analysis did not 
match patients with MRSA and MSSA bacteremia.  Potential confounders were 
controlled during statistical analysis.  A multivariable model was constructed that 
adjusted for whether a patient was receiving dialysis, involvement of prosthetic material, 
comorbidities, surgical wound source, bone and joint source and a severity of illness 
score.      
 Lodise et al. [12] characterized hospital costs in a retrospective cohort 
investigation.  Patients with infection caused by MRSA and MSSA were not matched, 
rather baseline characteristics (e.g., hospital stay before infection onset, APACHE II, age, 
source of bacteremia) were considered during statistical analysis.  The total costs of an 
infection caused by MRSA and MSSA was $21,577 and $11,668, respectively.  All cost 
data were log-transformed.  The cost information reported was the actual cost according 
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to the hospital where the investigation took place, the Detroit Receiving Hospital.  A 1.4-
fold (4.9 days) longer post-infection LOS was observed in MRSA patients.  This 
investigation was limited to ICU patients. 
Greiner et al. [16] evaluated the costs of nosocomial MRSA versus MSSA 
bacteremia in patients undergoing hemodialysis.  This retrospective analysis considered 
patients who were hospitalized in one of three German centers.  A German refined DRG 
system was used to calculate costs which were reported in Euros.  This investigation is 
especially important since it found no difference in MRSA vs. MSSA costs and it 
included data for three hospitals.  However, there were only 49 patients between the three 
hospitals.  This investigation was limited to patients with end stage renal disease. 
McHugh et al.[13] performed a case-control study to identify risk factors for 
developing MRSA bacteremia.  They did not initially match patients according to 
severity of illness.  However, patients were stratified into two groups based on their case-
mix index (CMI).  CMI is a hospital level average of individual patient DRGs.   
Therefore, CMI was used as a surrogate for severity of illness. They determined that the 
cost of MRSA bloodstream infection was higher by nearly 120% as compared to MSSA 
bloodstream infections when severity of illness was controlled.  Cost data appear to 
reflect costs from the entire hospitalization, not just the costs from infection onset to 
discharge.  Similar to the report by Lodise et al. [12] cost information appears to be 
institution specific.   
Abramson et al.[14] performed a pairwise-matched nested case-control study to 
examine the impact of MSSA and MRSA blood stream infections on length of hospital 
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stay, total costs and variable direct costs attributable to the infection.  MRSA infections 
had a higher median attributable cost than MSSA infections, $27,083 vs. $9,661 
respectively.  Costs were calculated using actual hospital costs (not charges) for the entire 
hospitalization.  The study matched MSSA and MRSA patients to non-infected hospital 
controls.  In a case-control design it is appropriate to match patients with an outcome 
(MRSA or MSSA) to the entire at risk population (non-infected hospital controls).  This 
design does not allow for direct comparison between the MRSA and MSSA groups while 
controlling for confounding.   
Reed et al.[15] conducted a cost analysis of MRSA vs. MSSA bacteremia, but 
their study was limited to patients receiving hemodialysis.  This study compared initial 
hospitalization costs and costs at 12 weeks after initial hospitalization. Initial 
hospitalization costs were $21,251 vs. $13,978 for MRSA and MSSA respectively.  
Twelve week costs were $25,518 vs. $17,354 for MRSA and MSSA respectively. 
The following investigations are not included in Table 2.2 above.  Their 
methodology was not as similar to the current study.  However, they will still be 
discussed as relevant background information.  
Kim et al. [50] performed an analysis to determine the economic burden of 
MRSA in a university-affiliated, tertiary-care hospital.  This analysis was not limited to 
MRSA bacteremia, other infection sites included soft tissue, surgical sites, pneumonia 
and osteomylitis.  Additionally, patients were not matched.  A chart review process was 
used to determine the attributable days of hospitalization for each MRSA infection.  
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Costs were then calculated for only attributable days of hospitalization.  All costs were 
reported in Canadian dollars.         
Similar to Kim et al., investigations by Capitano et al. [51], Kopp et al. [31] and 
Rubin et al. [52] were not limited to patients with SAB.   Even though Kopp et al. [31] 
did stratify based on infection location, cost information was not delineated based on 
location.  Also, patients were not matched according to severity of illness.  Rubin et al. 
[52] also stratified by type of infection, but did not match patients with MRSA to patients 
with MSSA.  An additional difference in the paper by Capitano et al. [51] was the long-
term care facility setting.  Data from long-term care facilities is not necessarily 
generalizable to hospitals.  However, all of these investigations reported higher 
costs/charges for treating MRSA infections.    
Chaix et al. [48] performed a cost-benefit analysis of an MRSA control program 
in an ICU with endemic MRSA.  They concluded that the mean cost attributable to 
MRSA infection was $9,275.  An unmatched case control study by Lepelletier et al.[49] 
also examined ICU costs.  The authors concluded that MRSA involved extra cost due to 
antimicrobial treatment and quantified that cost in euros.  Both of these French studies 
have limited external validity due to their ICU focus. 
The methodologies used in each of the above investigations have advantages and 
limitations.  The current study attempted to incorporate the strengths of these previous 
investigations whenever possible. 
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CHAPTER 3 
Preliminary Study 
 
Objectives  
  
1. Estimate the crude hospital charges for treating methicillin-resistant Staphylococcus 
aureus (MRSA) bacteremia. 
 
2. Measure the association between MRSA bacteremia and total hospital charges. 
 
3.  Estimate the adjusted hospital charges for treating MRSA bacteremia. 
 
Methods  
Study population 
 Eligible patients were those who had Staphylococcus aureus bacteremia (SAB) 
and were discharged from the Virginia Commonwealth University Health System 
27 
 
(VCUHS) between May 1, 2006, and April 31, 2007.  If a patient had more than one 
episode of SAB during their admission, only the first episode was considered.   
 
Study Design 
This was a retrospective cohort analysis within VCUHS.  Data were extracted for 
each patient from electronic medical records.  The exposure of interest was infection 
susceptibility, and the outcome was total hospital charges.  Patients with Staphylococcus 
aureus were assessed to be either resistant or susceptible to methicillin by the 
microbiology laboratory at VCUHS.  Susceptibility testing was performed and 
interpreted according to the Clinical and Laboratory Standards Institute (formerly the 
NCCLS) guidelines.[53]  The dependent variable, total hospital charge, was obtained 
from the hospital accounting department. 
 
Data Collection 
Data were collected from 2 databases within the hospital and integrated using 
medical record numbers.  First, the pathology database was electronically queried for 
patients with Staphylococcus aureus bacteremia (SAB).  Second, hospital accounting 
provided charge information for each SAB patient.   
 
Inclusion criteria 
Patients were eligible for inclusion if they were > 18 years old and had a blood 
culture obtained > 48 hours post admission.  The onset of infection was defined as the 
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time the blood culture was obtained.  The length of stay from admission to onset had to 
be at least 48 hours to infer hospital acquisition.  Patients who were transferred from 
another hospital, as noted by their admission source, were not required to be in the 
hospital for > 48 hours for inclusion in the analysis.   
 
Matching 
 Frequency matching on pre-infection LOS was used.  This ensured the groups had 
a similar duration of hospitalization before infection onset.  The confounding effects of 
pre-infection LOS on infection susceptibility and charge were controlled by matching.   
 
Statistical Analysis 
 Descriptive statistics were reported as median and inter-quartile range (IQR) since 
the outcome variable was not normally distributed.  Proportions between the groups were 
compared using Pearson’s chi-squared test.  Continuous variables were compared using 
the Wilcoxon Rank Sum test.  A two-sided alpha of 0.05 was considered significant.  
Statistical analysis was performed using JMP (version 7; SAS Institute, Cary, NC) and 
SAS (version 9.1.3; SAS Institute, Cary, NC) software. 
 The median crude hospital charge was approximated from the data for the overall 
sample and by infection susceptibility group.  The median adjusted hospital charge was 
calculated using a generalized linear model (GLM) with a gamma distribution and a log 
link. This method employs maximum-likelihood estimation.  The model’s predicted 
values were used to estimate the median hospital charge by infection susceptibility group. 
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 The association between total hospital charge and infection susceptibility status 
was measured by examining the infection susceptibility coefficient.  Exponentiated 
coefficients provide a ratio of means which can be re-expressed as the percentage 
increase in mean cost per unit increase in the covariate.[54]    
 Before building the multivariable model, potential predictor variables were 
assessed in univariate models.  Variables had to have a p-value < 0.25 for consideration 
in the multivariable model.   
 Since the association between susceptibility status and total hospital charge was 
being examined, susceptibility status remained in the model without attention to 
statistical significance.  Homogeneity of slope was assessed by evaluating the interaction 
terms between susceptibility status and each covariate. All one-way interactions were 
assessed. The likelihood ratio test was used to determine if the interaction terms belonged 
in the model.    
Known confounders (i.e., DRG weight and discharge status) were included in the 
model.  Potential covariates not involved in effect modification were assessed for 
confounding.  A change of more than 10% in the coefficient for susceptibility status was 
considered significant for confounding. 
Influential diagnostics were performed to identify observations that could greatly 
influence the multivariable model.  The standardized Pearson residual and hii were used 
to identify leverage, outlier and highly influential points.  The affected coefficients were 
identified using Cook’s D and DFBETAS.  A correlation matrix was used to assess the 
potential for pairwise multicollinearity.   
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Results 
 During the study period, 219 episodes of SAB were identified.  One hundred and 
thirty-seven patients failed to meet the inclusion criteria.  Of the remaining 82 patients, 
72 patients met the frequency matching criterion (MRSA = 45, MSSA = 27).  No MSSA 
patients were excluded by the frequency distribution matching.    
 The overall median total hospital charge was $140,396.  The charge for each 
group can be found in Table 3.1.  The crude difference in median charge was $80,771. 
 
Table 3.1 Crude hospital charge in US dollars 
 
  Median IQR Minimum Maximum
Overall 140,396 63,236 to 308,847 11,896 1,169,816 
MRSA 166,901 73,526 to 316,101 11,896 1,169,816 
MSSA 86,130 52,675 to 232,370 32,498 761,555 
IQR = interquartile range 
MRSA = methicillin-resistant Staplylococcus aureus 
MSSA = methicillin-susceptible Staplylococcus aureus 
   
The median ages for the MRSA and MSSA groups were 55 years old and 53 
years old, respectively.  The MRSA group was 53.3% male while 51.8% of the MSSA 
group was male.  The susceptible and resistant groups appear balanced with respect to the 
measured covariates.   
The results of the univariate GLMs are available in Table 4.  ICU status, age and 
DRG weight were significant at p<0.25.  Variables not significant in the univariate 
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analysis were not considered for multivariable model inclusion, with the exception of 
discharge status.  Discharge status was included since it was a known confounder.   
All two-way interaction effects between infection susceptibility status and the 
four potential modifiers (ICU status, DRG weight, age and discharge status) were 
assessed by including an interaction term for each in the multivariable model.  Likelihood 
ratio tests were used to compare the full and reduced models with different combinations 
of the interaction terms.  There were no significant interactions with infection 
susceptibility status.     
All possible two-way interactions between age, ICU status, DRG weight and 
discharge status were assessed using likelihood ratio tests as described above.  There 
were two significant interactions; DRG weight and ICU status as well as ICU status and 
age.  These interactions were retained in the model along with the two associated lower-
order terms.  No variables were assessed for confounding.  All model variables were 
either involved in effect modification or were known confounders.   
The final model included organism (infection susceptibility status), DRG weight, 
ICU, age, discharge status, an interaction between DRG weight and ICU and an 
interaction between ICU and age.  The parameter estimates were exponentiated for 
interpretation (Table 3.2.)  
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Table 3.2. Multivariable model exponentiated coefficients (hospital charge = dependent 
variable) 
 
Parameter 
Exponentiated 
Coefficient 
Standard 
Error 
Wald 95% Confidence 
Limits 
Organism 1.276 1.16 0.95 1.71 
DRG weight 1.455 1.11 1.18 1.79 
ICU status 1.437 1.79 0.46 4.47 
Age 0.985 1.01 0.97 1.00 
Discharge status 0.845 1.22 0.57 1.25 
Age x ICU status 1.026 1.01 1.01 1.05 
DRG weight x ICU status 0.743 1.11 0.60 0.94 
Organism = infection susceptibility (MRSA vs. MSSA) 
DRG = diagnosis related group 
ICU = intensive care unit 
 
No pairwise multicollinearity was found.  There were no leverage points but six 
observations were identified as outliers.  The analysis was rerun without the outliers and 
the parameter estimates were within the original model’s confidence intervals; thus, 
removing the outliers did not alter the regression coefficients.  Cook’s D identified seven 
observations that may be affecting the regression coefficient estimates.  The DFBETAS 
for these observations indicated the regression coefficient most influenced was the scale 
parameter. 
The multivariable model predicted an overall charge of $163,811 (IQR $117,029 
to $230,954).  The MRSA and MSSA median charges are presented in Table 3.3.   
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Table 3.3. Predicted charges 
 
 Overall MRSA  MSSA 
     Median ($) 163,811 186,559 145,345 
     IQR ($) 117,029 to 230,954 125,324 to 308,003 101,440 to 187,123 
IQR = inter-qurtile range 
MRSA = methicillin-resistant Staphylococcus aureus 
MSSA = methicillin-susceptible Staphylococcus aureus 
 
According to the model, a case of MRSA bacteremia is expected to cost $41,214 
more than a case of MSSA bacteremia.  This represents a mean increase of 28% for 
MRSA over MSSA bacteremias.   
  
Discussion  
 According to the multivariable model, a case of MRSA bacteremia will have 28% 
higher costs than an MSSA bacteremia.  The 95% confidence interval for this estimate 
ranges from 5% decrease to a 71% increase.  Since the confidence interval included no 
difference (i.e., 1), there is not a statistically different mean charge between the 2 groups.  
The point estimate was, however, consistent with the 44% increase published in another 
report.[55]  Being discharged alive from the hospital (as opposed to expiring during 
admission) is associated with a decrease in charge by 15%.   
DRG weight, ICU status and age are all involved in effect modification and 
therefore must be interpreted in light of that interaction.  The impact of age while not in 
the ICU would be a decrease in charge by 1.5% for each additional year of life.  In the 
ICU, each additional year increases charges by 1%.  The impact of a one unit increase in 
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DRG weight when not in the ICU would be an increase in charge of 46%.  In the ICU, 
each unit increase in DRG weight would only increase charges by 8%.   
The literature has reported differences in charge as ranging from $5,000 to 
$40,000 [11-14, 56-59] The crude difference in charge between MRSA and MSSA, 
$80,771, was much greater than previously reported values.  The adjusted difference in 
charge, $41,214, was still slightly higher than values reported in other investigations.  
This study found a 1.28-fold increase in charges associated with MRSA bacteremia as 
compared to MSSA bacteremia.  This is consistent with previous reports which report a 
1.2-to 2-fold increase.[12, 13]  
Previous methods for calculating the economic burden of resistance have varied 
largely.  Many single center investigations were able to collect actual cost from their 
institution.[12, 14, 15]  Another investigation was able to identify only costs associated 
with the SAB.[16]  And one of these investigations was able to collect costs attributable 
to SAB after hospital discharge.[16]  Charges were not able to be sub-categorized in this 
analysis since only an overall aggregate charge was available for each subject.   
Since charges are known to inflate the economic burden of hospitalization, cost-
to-charge ratios have been used to better approximate actual cost from charges [11]; 
however, cost-to-charge ratios are a poor approximation of actual costs [30], which is 
why they were not used in this investigations.  Hospital charges are considered to be a 
gross overestimation of the true hospitalization cost but, the difference between MRSA 
and MSSA bacteremia for charge and cost has been shown to be similar.[31] 
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As previously stated, adjusting for underlying severity of illness was a major 
concern in this investigation.  There is currently no well-validated illness severity score 
for infectious disease outcomes.[27]  Other investigations have used a variety of 
techniques including APACHE score [12, 18], McCabe/Jackson score [11] and the 
Charlson comorbidity score.[60]  The APACHE score is intended for use with ICU 
patients while the McCabe/Jackson score has been evaluated for non-ICU patients.  The 
calculation of the Charlson comorbidity score required parameters not available in this 
analysis (i.e. multiple ICD-9-CM diagnosis codes).  This lack of information precluded 
the calculation of a Charlson comorbidity score.  DRGs have been used as a surrogate for 
severity of underlying illness in MRSA bacteremia.[13]  This approach was originally 
developed to accurately assess the cost of hospitalization by adjusting for severity of 
illness within the DRG classification scheme.[46, 47]  This investigation used DRG 
weights to adjust for severity of underlying illness.  
 This analysis is based on two fundamental assumptions.  First, the charges prior to 
infection onset are comparable between the MRSA and MSSA groups.  The VCUHS 
billing department provided one charge for the entire hospitalization.  Charges were not 
available as pre- and post-infection charges.  Differences in pre-infection charges could 
bias the study results.  Specifically, the difference in total hospital charge would be 
overestimated if pre-infection charges were higher in the MRSA group.  The difference 
would be underestimated if the pre-infection charges were higher in the MSSA group.  
Second, the charges are assumed to be a result of the resistant or susceptible bacteremia.  
Hospital charges unrelated to the bacteremia introduce bias into the investigation and also 
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inflate the difference in hospital charges between the MRSA and MSSA and overestimate 
charge.  There is no indication that either assumption was violated.   
 There were several additional limitations in this investigation.  The study relied 
on previously collected data.  Retrospective data can be convenient since the researcher 
does not have to wait for the data to be prospectively collected.  However, records must 
be complete and accurate or the results will be biased.[61]  This dataset contained no 
missing data.    
The small sample size of this investigation limited its precision.  This and all 
previous investigations are plagued by their small sample size.  The size of this 
investigation was comparable to the size of previous reports.  A multi-center 
investigation is needed to adequately power an investigation to achieve accurate and 
precise estimates.[4] 
 No attempt was made to estimate the charges associated with infection control. It 
was assumed that any infection control measures would be the same for all patients 
within the study timeframe since all patients were from the same hospital.  It should be 
noted that the incidence of MRSA infections can be reduced substantially through 
prevention.[62]   
 Finally, the modeling technique used also greatly influenced the results. The use 
of GLMs is not without limitations.  The choice of link function and distribution can 
greatly impact the model’s success.  The distribution and link function were appropriately 
defined prior to analysis; however, the exploration of different link functions and 
distributions may have altered the parameter estimates.  Although the impact of outliers is 
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minimized, extreme charge values can still influence parameter estimates.[63]  The 
impact of outliers in this investigation is thought to be minimal since the removal of 
outliers did not significantly change the parameter estimates.  The last modeling 
limitation could probably be more accurately referred to as investigator naivety.  Many 
unanticipated problems arose using the specified GLM.  For example, many of the 
influential diagnostics that are computed automatically for linear regression were not 
available using PROC GENMOD in SAS. Fortunately the SAS Institute has published 
some macros that compute some of these diagnostics, but adapting the macro to the study 
data was less than intuitive.    
 The results of this investigation are similar in generalizability to the previous 
investigations.  The study was performed in a large tertiary care teaching hospital where 
patient acuity is relatively high.  These results may not extend to a community hospital.   
To increase external validity, any future investigations should include a variety of 
hospitals with differing characteristics.   
 
Conclusion 
The purpose of this investigation was to quantify the additional hospitalization 
charge attributable to methicillin-resistant vs. methicillin-susceptible SAB.  This 
objective was achieved by estimating the crude hospital charge for treating MRSA and 
MSSA bacteremia, measuring the association between MRSA bacteremia and total 
hospital charges, and estimating the adjusted hospital charge for treating MRSA 
bacteremia. 
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 The crude “cost of resistance” for treating MRSA bacteremia was estimated and 
the association between MRSA bacteremia and total hospital charges was explored. The 
crude difference in hospital charges was $80,771 and the adjusted difference was 
$41,214.  The model accounted for around half of the disparity in cost.  The association 
between bacteremia susceptibility status and hospital charges was a 1.28-fold increase for 
resistant infections.   
 Future research in this area is still needed. A large, multi-center investigation 
needs to be performed to more precisely estimate the association between MRSA/MSSA 
bacteremia and hospital charges.  Also, investigation is needed to explore the relationship 
between susceptibility status, pre- and post-infection length of stay and hospital charges. 
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CHAPTER 4 
Methods 
  
Data Source 
Cerner HealthFacts (Cerner Corporation, Kansas City, MO) is a national data 
warehouse that represents the electronic patient charts from millions of inpatient 
admissions and emergency department and outpatient visits at U.S. healthcare 
organizations.[64]   
Within Cerner HealthFacts, patient records (UB-92/UB-04 standard format) 
contain detailed information on inpatient care.  This includes: principle and secondary 
diagnosis codes (in International Classification of Diseases, 9th Revision, Clinical 
Modification [ICD-9-CM] format), inpatient procedure codes (in ICD-9-CM format), 
patient demographic information (age, insurer and gender) and hospital demographic 
information (teaching status and urban/rural).  The database also contains admission and 
discharge dates as well as time stamped microbiologic susceptibility to methicillin for 
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bacteremia. The analysis was conducted from a hospital perspective.  Therefore, only 
data elements which were important from a hospital perspective were considered.  
DRG relative weights from 2006 were used as listed by the Centers for Medicare 
and Medicaid Services (CMS) in the Acute Inpatient files for download.[65]   The 
weights were integrated into the project database.  As previously discussed, each DRG 
code was assigned a relative weight.  DRG weights from 2006 were used since all 
charges were adjusted to their 2006 value.  These relative weights are publically available 
through CMS. 
 
Study population 
 The data warehouse was electronically queried for patients with Staphylococcus 
aureus bacteremia (SAB).  Eligible patients were those who had SAB and were 
discharged by a hospital whose data were collected by the Cerner HealthFacts between 
January 1, 2000, and December 31, 2006.  So that every observation within a hospital 
was independent, only the first episode of SAB per patient was considered.   
  
Inclusion and Exclusion Criteria 
Inclusion criteria include: age > 18 years old and onset of infection > 48 hours 
post admission.  The length of stay from admission to onset must have been at least 48 
hours to infer hospital acquisition.  Patients who were transferred from another hospital 
as their admission source were excluded.    
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Study Design 
This was a retrospective cohort analysis using the Cerner HealthFacts data 
warehouse.  The exposure of interest was infection susceptibility, and the outcomes were 
post-infection LOS and total hospital charges.  Patients were identified as having SAB 
according to microbiologic susceptibility determined by the hospital’s microbiologic 
laboratory.  Infection susceptibility standards were developed by the Clinical and 
Laboratory Standards Institute (formerly the NCCLS) guidelines[53]. 
 
Matching 
 Frequency matching is a technique that can be used to achieve reasonable 
efficiency between two groups.  This investigation used frequency matching by pre-
infection LOS to exclude observations with an extremely long pre-infection LOS.  The 
MRSA and MSSA groups should have similar hospital lengths of stays before infection 
onset.  However, the confounding effects of pre-infection LOS on infection susceptibility 
and charge cannot be completely controlled by frequency matching.  Therefore, pre-
infection LOS was also used as a variable in the multivariable model.[66] 
 
Outcomes 
There were two outcomes of interest in this analysis.  First, post-infection LOS in 
days was evaluated.  For the purposes of this analysis, LOS was divided into two parts.  
The pre-infection LOS is the LOS from admission to the time when the initial positive 
blood culture was drawn.  For this analysis, the time of blood culture is referred to as the 
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infection onset.  The post-infection LOS is the LOS from infection onset to discharge.  
This distinction attempted to designate the hospital stay attributed to the SAB from the 
stay attributed to the primary reason for hospitalization.   
 Second, total charges in US dollars were assessed.  Charges were adjusted for 
inflation using the 2006 Consumer Price Index for hospitals.[67]  When comparing 
economic values over multiple years the relative value of money must be considered.  
Normally, money is worth less in the future than it is worth today.  Therefore, past dollars 
must be adjusted for inflation.[68]   
The consumer price index (CPI) measures the average change over time of goods 
and services and is generally used as a measure of inflation.  The reference index for the 
CPI is set at 100 which represents the average price level for the 36 month period 
between 1982 and 1984.  The reported annual CPI reports a change relative to the 
reference index.  For example, an index of 120 would mean that there has been a 20% 
increase in price since the reference period.  An index less than 100 would reflect a 
decrease in price.  Movements of the index from one date to another can be expressed as 
the difference between index levels.  But, it is more useful to express the movements as 
percent changes.  The CPI allows for comparisons of consumer costs over time.  Table 
4.1 below shows the CPI of medical care services that pertain to hospital and related 
services. 
 
  
43 
 
Table 4.1. Consumer Price Indexes for Hospital and Related Services: 2000 to 2006 
CPI for Hospital and Related 
Services 
Percent change from previous 
year 
2000 317.3 
2001 338.3 6.62 
2002 367.8 8.72 
2003 394.8 7.34 
2004 417.9 5.85 
2005 439.9 5.26 
2006 468.1 6.41 
CPI = Consumer Price Index 
 
Statistical Analysis by Objective 
 Statistical analysis was performed using JMP (version 7; SAS Institute, Cary, NC) 
and SAS (version 9.1.3; SAS Institute, Cary, NC) software. JMP was primarily used for 
descriptive statistics while SAS was used for the GLM and path analysis. Proportions 
between the groups were compared using Pearson’s chi-square.  Continuous variables 
were compared using a Wilcoxon Rank Sum test.  A two-sided alpha of 0.05 was 
considered significant.  The following statistical methods were used to address each 
objective. 
Modeling economic data is less than straightforward.  The most commonly used 
regression technique, ordinary least squares (OLS), is not generally appropriate for the 
following reasons.[69]  First, the dependent variable, total hospital charge, is rarely 
normally distributed.  The typical distribution is bounded by zero with a long right tail 
(most closely resembling a gamma distribution).  OLS requires the error terms to be 
normally distributed for statistical inference.  The second problem with OLS is the 
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homogeneous variance assumption.  With economic data the variance often increases as 
the mean increases making OLS inappropriate.  Several statistical solutions have been 
proposed to more appropriately model charges. 
A log transformation can be performed to make the dependent variable more 
normally distributed.  However, resulting estimates are in terms of “log charges.” This 
often leads to problems with interpretation.  Smearing factors have been used to 
transform economic data from logarithmic back to natural units, but these factors can 
introduce substantial bias in the presence of heteroscedasticity.[70]   
A generalized linear model (GLM) can be used to create virtually any model.  The 
most appropriate distributions for cost data would be the gamma or inverse Gaussian 
distribution.[71]  Both of these distributions are appropriate for non-zero continuous 
outcomes.  However, most economic data analysis utilizes the gamma distribution.[54]  
The gamma distribution is also appropriate since it assumes that variance is proportional 
to the square of the mean.  Economic data is non-zero, continuous and usually has a 
variance which increases with the mean.  The negative binomial distribution would not be 
appropriate since it assumes a categorical outcome.  The link function is not a 
transformation on the data, but a transformation of the population mean.  The most 
commonly used link function for economic analysis is the log link.[54]  Although the log 
link is not the canonical link function for the gamma distribution, it has been used to 
analyze cost data because it will not predict a negative value. Using the log link, an 
exponentiated coefficient provides a ratio of the means.[54]   
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 Observational investigations attempt to estimate the effect of an exposure by 
comparing outcomes for subjects not randomly assigned to the exposure of interest.[72]  
In randomized clinical trials, random assignment serves to balance covariates so that the 
study groups are comparable with respect to the distribution of their covariates.[73]  The 
presence of dissimilar groups can introduce systematic error into an observational 
study.[61]   
 The theory of counterfactuals contemplates the outcome of the exposed group if 
there was no exposure or conversely the outcome of the unexposed if there had been 
exposure. The term “counterfactuals” indicates that at least one of the two circumstances 
is contrary to fact.[6]  There is no way to estimate the counterfactuals, but the bias of the 
estimates can be corrected through the predicted probability of exposed vs. unexposed 
using observed predictors.  The predicted counterfactual can be estimated using 
propensity scores. 
 Propensity scores are the probability of exposure given measured baseline 
variables.[9]  Observational studies employ this method to adjust for observable bias with 
the goal being to eliminate bias from unequal distribution of confounders.  To do this, a 
group of likely confounders is converted into one scalar score through a two-stage 
process.  The actual propensity score is unknown and therefore must be estimated using a 
logit or probit regression model  where the dependent variable is exposure status and the 
independent variables are the potential confounders.[74]  The score is the probability (0 ≤ 
propensity score ≤ 1) of receiving the treatment (i.e., exposure) based on the set of 
identified covariates as predicted by the first stage regression model.  The score can be 
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used as a matching or stratification factor, as a covariate in multivariable model or to 
perform inverse probability of exposure weighting.[10]  
 Propensity scores can be used to match patients between exposure groups on 
multiple confounders.  However, the possibility of over-matching must be considered.  
This occurs when matching is done incorrectly or unnecessarily. The more variables used 
to calculate the propensity score, the greater the likelihood of overmatching.  To avoid 
overmatching, the propensity score should preferably include only established 
confounders.[75]          
 As previously discussed, stratification becomes difficult when many confounders 
are present since there are not enough observations in each stratum.  Stratification on 
propensity score limits the number of stratum thus making stratification a more robust 
method to control for confounding.[76] 
If the score is used in a multivariable model, the second part of the two-stage 
regression process is the traditional model where the dependent variable is the outcome 
of interest and the propensity score is used as a covariate.  The advantage of including 
propensity scores over traditional regression is in not over-parameterizing the model. [77]  
Normally each confounder would require one degree of freedom (df) while the propensity 
score, which could be comprised of many confounders, only requires 1 df.   
 Several papers have been published exploring propensity score methodology.[9, 
74, 78]  Of particular interest, an investigation examining the economic impact of MRSA 
bacteremia used propensity scores.[15] The propensity score was calculated using 
demographic characteristics, comorbidities, risk factors, clinical characteristics and 
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infection related factors.  It was then used as an independent variable in the multivariable 
model.  This investigation will be discussed more fully later in this report.   
 Propensity scores are not without limitation.  They do not balance uncorrelated, 
unmeasured characteristics and confounders.[79]  Unmeasured confounding can be dealt 
with using other methods.  Additionally, covariates cannot be used that are directly 
affected by the exposure of interest.[80]  If the covariate is directly affected by the 
exposure, it may be an intermediary not a confounder.  Including an intermediary in the 
propensity score would introduce bias into the investigation.  Lastly, the models used to 
generate the propensity score rely on the same assumptions as logistic regression.  If the 
model uses the propensity score as a continuous variable, the assumption of a (log-) 
linear association with the dependent variable must be tested using categories. The 
covariates must be balanced across the groups.[81]  
 
Objective 1: Measure the crude difference between infection susceptibility status MRSA 
vs. MSSA bacteremia and total hospital charges.   
 This aim was accomplished by subtracting the mean MSSA charge from the mean 
MRSA charge.  The charges were compared using a Wilcoxon Rank Sum test. 
Additionally, trends in hospital charge over the study period were examined using 
repeated measures analysis of variance (ANOVA).  Tukey’s HSD was performed if a 
significant difference was found.   
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Objective 2: Determine the impact of methicillin resistance vs. methicillin susceptibility 
in SAB on total hospital charges while adjusting for potential confounders. 
 The impact of infection type on hospital charge was calculated using a GLM with 
a gamma distribution and a log link while adjusting for various factors. This method 
employs maximum-likelihood estimation.  Variables with a univariate p-value < 0.25 
were eligible for inclusion in the multivariable model.  Known confounders (e.g. severity 
of illness, DRG weight) and potential covariates were eligible for inclusion.  A 
propensity score was used to include hospital level factors (e.g., hospital teaching status, 
urban/rural status).  Propensity scores require a two stage regression procedure.  In the 
first stage, the outcome variable was infection susceptibility and the independent 
variables were the hospital level factors.  The second stage was the multivariable model 
where the predicted value from the first model was used as an independent variable.  The 
covariates were checked for balance.  Using the predicted values from the multivariable 
regression model, the mean charge of MSSA bacteremia was subtracted from the mean 
charge of MRSA bacteremia.   
 
Objective 3: Determine the impact of methicillin resistance vs. methicillin susceptibility 
in SAB on post-infection LOS while adjusting for potential confounders. 
 The impact of infection type on post-infection LOS was calculated using a GLM 
with a gamma distribution and a log link while adjusting for various factors. This method 
employs maximum-likelihood estimation.  Variables with a univariate p-value < 0.25 
were eligible for inclusion in the multivariable model.  Known confounders (e.g., severity 
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of illness, DRG weight) and potential covariates were eligible for inclusion.  A 
propensity score was used to include hospital level factors (e.g., hospital teaching status, 
urban/rural status).  Propensity scores require a two stage regression procedure.  In the 
first stage, the outcome variable was infection susceptibility and the independent 
variables were the hospital level factors.  The second stage was the multivariable model 
where the predicted value from the first model was used as an independent variable.  The 
covariates were checked for balance.  Using the predicted values from the multivariable 
regression model, the mean LOS of MSSA bacteremia was subtracted from the mean 
LOS of MRSA bacteremia.   
  
Objective 4: Describe the relationship between SAB methicillin susceptibility, LOS and 
total hospital charges using path analysis. 
Path Analysis is a type of analysis that uses multiple regression modeling to 
explore complex relationships.  The purpose is to provide estimates of the magnitude and 
significance of hypothesized connections between variables.  As previously discussed, 
the relationship between hospital LOS and total hospital charges is not simple.  Post-
infection LOS is an intermediate between infection susceptibility and hospital charges.  
Although pre-infection LOS confounds the relationship between infection susceptibility 
and charge, there is also a relationship between pre infection and post-infection LOS.  
The complex relationships involving LOS can be explored using path analysis.  
There are 5 general steps in path analysis.[82]  First, the model must be specified, 
which involves formally stating the proposed model.  Specification is probably the most 
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important step because if the model is incorrect the results will be meaningless.  Of note, 
variables in path analysis need to be continuous except if the variable represents group 
membership or is an exogenous variable.  Categorical variables cannot be 
endogenous.[82]  Second, the model must be identified.  Identification refers to verifying 
the specific model assumptions.  Similar to regression, observations need to be 
independent, normally distributed and have uniform variances.[82]  Third, the model is 
estimated.  Logistically, this occurs using a series of regression models.  Many statistical 
software packages are available that perform this function.  Fourth, the fit of the model is 
tested.  The fit of the model is good if the fitting function is close to zero.  If the ratio 
between chi-square and the degrees of freedom is less than 2, then the model fit is 
good.[83]  Finally, the model can be manipulated.  This can be useful especially if the 
model fit is not good.  
The proposed path analysis model is diagramed below in Figure 4.1.  The direct 
and indirect impact of one variable on another can be estimated.[82]  Direct effects are 
represented when a single arrow connects two variables.  Indirect effects are defined 
when no single line directly connects two variables, but instead, the variables are 
connected through one or more other variables along their path.[84]  Indirect effects 
measure the impact of intermediates or mediator variables.[82]  The endogenous 
structural equations used that correspond to Figure 4.1 are described below in Equations 
4.1 to 4.2.  The model will be tested using SAS’s PROC CALIS.  The model fit was 
assessed using chi square. 
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Figure 4.1. Path Analysis diagram 
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Post-infection LOS = b31 x susceptibility status + b32 x pre-infection LOS + e3 Eq. 4.1
 
Charge = b43 x post-infection LOS + b42 x pre-infection LOS + e4  Eq. 4.2
 
Human Subjects Protection and Data Privacy 
 The largest potential risk for the subjects was exposure of medical information.  
To ensure minimal risk to the patients, the data were coded and encrypted. The data did 
not contain patients’ medical record numbers. Access to the dataset was restricted to 
those individuals listed on this protocol, and the dataset was centrally maintained in a 
password-protected environment.  Multiple copies of the data were minimized.  In the 
event that additional copies of the dataset were required for the conduct of the study, the 
principle investigator maintained a list of those copies and ensured that all extra copies 
were appropriately destroyed once analysis was finished so that only one copy was 
retained to satisfy university record keeping policies relevant to research data.  Disclosure 
of information did not take place without the expressed written permission of Cerner 
HealthFacts or required by law.  Data within HealthFacts is compliant with the Health 
Insurance Portability and Accountability Act of 1996 (HIPAA).  Results will be 
published in such a way that no subject will be individually identifiable.  This study 
qualified for exemption according to 45 CFR 46.101(b) Category 4 at Virginia 
Commonwealth University internal review board (IRB). (VCU IRB#: HM11841).  A 
copy of the IRB Approval form can be found in Appendix A. 
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CHAPTER 5 
Results 
 
Data Manipulation 
Data from the Cerner HeathFacts data warehouse were received as numerous files 
that were cleaned by a programmer.  The flow chart below (Figure 5.1) outlines the 
general methodology the programmer used to extract and combine the data.  Data fields 
were extracted that contained the variables of interest when: (1) the patient age was 
greater than 18 years old, (2) discharge date was between 2000 and 2006, (3) collection 
source key of blood, and (4) isolate key for Staphylococcus aureus.  Files that contained 
the variables of interest were joined so that all the necessary data elements were 
contained in two datasets.  The first dataset contained the microbiologic information 
(referred to as Micro) and the second dataset included all the other variables including 
time stamped dates (referred to as Large).  The programmer also deleted duplicate 
observations.  Only observations that contained identical information for all data 
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elements were excluded here.  Data were provided to the investigator in a much improved 
form, but some manipulation was still required.    
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Figure 5.1. Flow chart used by programmer for data retrieval 
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The Micro dataset contained a unique patient identified and recorded isolate 
susceptibilities.  These susceptibilities contained a variety of values, such as resistant, 
susceptible, null and moderately sensitive.  Only observations where susceptibilities were 
reported as resistant or susceptible were retained in the dataset.  All microbiologic 
susceptibility testing was done with oxacillin or methicillin.  Some patients had both a 
resistant and a susceptible isolates (n=263).  A flowchart describing this cleaning process 
is available below (Figure 5.2).   
The Large dataset contained all other data elements.  Patients were excluded if 
their pre-infection length of stay (LOS) was less than two days.  Duplicate patients were 
removed for a final Large dataset n=3,313.  The Micro and Large datasets were merged 
creating one dataset with 1,088 patients.   A flowchart is provided below in Figure 5.2.   
A substantial number of patients in both the Micro and Large datasets were 
excluded during the merge since the datasets contained observations from different 
hospitals.  Table 5.1 below shows the number of excluded hospitals per year. 
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Figure 5.2 Flow chart used by investigator for data manipulation 
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58 
 
Table 5.1 Number of Hospitals excluded by the merge of Micro and Large datasets 
 
  
Merged Dataset 
(Micro + Large) Large Dataset Excluded Hospitals 
2000 9 9 0 
2001 15 16 1 
2002 13 18 5 
2003 17 20 3 
2004 15 19 4 
2005 14 26 12 
2006 22 32 10 
 
 
Relative DRG weights, publically available through CMS, for 2006 were added 
into the dataset.[65]  Some DRGs from earlier years were no longer valid in 2006, 
meaning the codes were no longer used.  The patients with the invalid DRG codes were 
removed (n=966).  A Charlson comorbidity score was calculated for each patient.   
After examining the pre-infection LOS distributions for MRSA (Figure 5.3) and 
MSSA (Figure 5.4), frequency matching was performed.  Only one MSSA observation 
had a pre-infection LOS longer than 62 days (circled below in Figure 5.4).  There were 
eight MRSA patients excluded.  Therefore, patients with a pre-infection LOS greater than 
62 days were excluded from the analysis (n=957).  
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Figure 5.3 Distribution of pre-infection LOS (MRSA) 
 
Figure 5.4 Distribution of pre-infection LOS (MSSA) 
 
0 10 25 40 55 70 85 100 115 130
Days
0 10 25 40 55 70 85 100 115 130
Days
60 
 
The dataset was then examined for erroneous data points.  Some observations 
existed with a negative LOS.  These observations were removed.  Some observations 
reported incredibly low charges (less than $100).  There was not a previously defined 
method to deal with this scenario.  The data were explored but there was no apparent 
pattern to the low charges.  The investigator chose a reasonably prudent criterion for 
inclusion that would exclude patients with an unrealistically low charge. The pilot 
investigation had a minimum charge of $11,896.  Patients with charges less than $11,896 
and with LOS ≥ 9 days were assumed spurious and were removed.  The final dataset 
contained 930 observations.  See Figure 5.5 below. 
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Figure 5.5 Flowchart leading to final dataset 
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Hospital charges were inflated to their 2006 value. CPI adjusted rates 
(compounded annually) were calculated for each year.  Table 5.2 below assumed a $1.00 
reference value.  Total hospital charges were adjusted to the 2006 by multiplying the 
reported charge by the CPI adjusted rate.  For example, 2000 values were increased by 
48%, and 2001 values by 38% to estimate their 2006 value.  Figure 5.6 below shows step 
by step how the CPI adjusted rates were calculated.  The inflation rates can be found in 
Table 4.1. 
 
Table 5.2 CPI adjusted rates 
2000 to 
2006 
2001 to 
2006 
2002 to 
2006 
2003 to 
2006 
2004 to 
2006 
2005 to 
2006 
2000 1 
2001 1.07 1 
2002 1.16 1.09 1 
2003 1.24 1.17 1.07 1 
2004 1.32 1.24 1.14 1.06 1 
2005 1.39 1.30 1.20 1.11 1.05 1 
2006 1.48 1.38 1.27 1.19 1.12 1.06 
CPI = Consumer Price Index 
 
Figure 5.6 Calculation of CPI adjusted rate 
 
 
 
  
2000 to 2001 had an inflation rate of 6.62% 
2001 to 2002 had an inflation rate of 8.72% 
 
Assuming the value in 2000 was $1, the value in 2001 would be: 
 $1.00 x (1 + 0.0662) = $1.07  
 
The value in 2002 would be: $1.07 x (1 + 0.0872) = $1.16. 
 
This means that the adjusted inflation rate for 2000 to 2002 was 16%. 
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Descriptive Statistics 
Demographic data for the categorical variables (admission source, payer type, and 
discharge disposition) are described below in Tables 5.3.  There were more categories for 
each categorical variable that were collapsed.  Additional categories can be found in 
Appendix B.  Of the 930 patients, 546 were MRSA (58.7%) and 384 were MSSA 
(41.3%).  There was a significant difference in admission source (χ2 = 10.43, df = 3, p-
value = 0.0152).  More MSSA were admitted from the Emergency Room and more 
MRSA patients were transferred to the hospital.  There was also a significant difference 
in discharge status (χ2 = 19.55, df = 5, p-value = 0.0015).  More MSSA patients were 
discharged and more MRSA patients expired in the hospital.  Discharge status was 
examined strictly as alive, dead or not available; 30.8% of MRSA patients expired in the 
hospital compared to 21.4% of MSSA patients (χ2 = 11.92, df = 2, p-value = 0.0026).  A 
p-value was not calculated for the payer status since a majority of the patients had data 
classified as not available.  The groups were balanced with respect to gender; the MRSA 
group was 53.5% male while 53.4% of the MSSA group was male (χ2 = 0.008, df = 1, p-
value = 0.9773).   
Demographic data for the continuous variables can be found in Table 5.4.  Data is 
reported as medians and interquartile ranges since the variables were not normally 
distributed.  The Wilcoxon Rank Sum test indicated all continuous variables were 
significantly different between the MRSA and MSSA groups except post-infection LOS.   
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Table 5.3 Descriptive statistics for categorical variables (n=930) 
 
  
MRSA      
  n (column %)    
MSSA 
n (column %)   
Total  
n 
Admission Source p-value = 0.0152 
Referral 96 (17.6) 68 (17.7) 164 
Transfer 55 (10.1) 19 (4.9) 74 
Emergency Room 261 (47.8) 212 (55.2) 473 
Not available 134 (24.5) 85 (22.1) 219 
546  384  
Discharge Status p-value = 0.0015 
Discharged  163 (29.9) 151 (39.3) 314 
Transferred  172 (31.5) 120 (31.3) 292 
Hospice 16 (2.9) 9 (2.3) 25 
Expired 168 (30.8) 82 (21.4) 250 
Other 5 (0.9) 11 (2.9) 16 
Not available 22 (4.0) 11 (2.9) 33 
 546 384  
Payer Type p-value= not calculated 
 Insured 33 (6.0) 35 (9.1) 68 
Medicare 20 (3.7) 15 (3.9) 35 
Medicaid 145 (26.6) 85 (22.1) 230 
Self Pay 9 (1.6) 3 (0.8) 12 
Not available 339 (62.1) 246 (64.1) 585 
546 384 
MRSA = methicillin-resistant Staphylococcus aureus 
MSSA = methicillin-susceptible Staphylococcus aureus 
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Table 5.4 Descriptive statistics for continuous variables (n=930)  
 
  MRSA MSSA   
Variable Median IQR Median IQR p-value 
Age 1 72 59 to 80 67 53 to 78 0.0003 
Charlson 
comorbidity score 1.00 0 to 2.00 1.00 0 to 2.00 0.0138 
DRG weight 1.68 1.21 to 3.07 1.35 1.04 to 2.39 0.0004 
Pre-infection LOS2 6 3 to 12 6 2 to 7 <0.0001 
Post-infection LOS2 6 2 to 14 6 3 to 12 0.6039 
Total LOS2  15 9 to 25   12 8 to 19   <0.0001 
MRSA = methicillin-resistant Staphylococcus aureus 
MSSA = methicillin-susceptible Staphylococcus aureus 
IQR = interquartile range 
DRG = diagnosis related group 
LOS = length of stay 
1 Age was measured in years 
2 LOS was measured in days 
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Objective 1:  
Crude difference in hospital charge by infection susceptibility 
 
 The total mean hospital charge was $111,636.  The charge for each group can be 
found below in Table 5.5.  The crude difference in mean charge was $24,406. Using the 
Wilcoxon Rank Sum, there was no difference between the MRSA and MSSA groups (p-
value < 0.0001). 
 
Table 5.5 Crude hospital charge in US dollars 
 
  Mean SD Median IQR Minimum Maximum
Overall 111,636 241,211 59,764 30,751 121,956 3,323 3,392,801
MRSA 121,713 252,465 68,013 33,247 131,060 4,035 3,392,801
MSSA 97,307 223,781 49,199 27,338 98,898 3,323 2,957,732
US = United States 
SD = standard deviation 
IQR = interquartile range 
MRSA = methicillin-resistant Staplylococcus aureus 
MSSA = methicillin-susceptible Staplylococcus aureus 
 
The intention was to perform repeated measures ANOVA.  However, only four 
hospitals had data every year from 2000 through 2006.  Since four hospitals represent a 
small fraction of the datasets, repeated measures ANOVA was not appropriate.  Instead, 
descriptive statistics were analyzed graphically to see if a difference appeared within the 
study period.   
Descriptive statistics for total charge by discharge year are presented below 
(Tables 5.6 and 5.7).  “N” represents the number of observations per year.  The mean for 
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2001 was much higher than any other year.  The maximum values for 2001 were 
$3,392,801 and $2,957,732 for MRSA and MSSA respectively.  There were five extreme 
values in 2001 which artificially inflated the 2001 mean.  All the other observations 
appeared within one standard deviation of one another.  Starting in 2002, there did appear 
to be a slight downward trend in the MSSA mean charge.  However, this trend was not 
echoed by the MRSA data.  
Boxplots for the total charges per year are below in Figure 5.7.  The boxplot is 
labeled with the number of outliers per year.  For the purposes of this figure, an outlier 
was defined as above the 75th percentile.  Of note are five extreme outlier observations 
for 2001.  They represent both MRSA and MSSA cases.  In Figure 5.8, the interquartile 
ranges have been enlarged to more closely examine the means which are depicted by red 
triangles.  The only mean that appeared different was 2001.  This mean was extreme due 
to five extreme outliers that will be addressed later in the analysis. An alternative 
statistical test, instead of repeated measures ANOVA, was not pursued further since there 
was no visually apparent difference in the means.   
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Table 5.6 Descriptive statistics for total hospital charge by discharge year for MRSA 
 
Discharge year N Mean Std Dev Min Max 
2000 35 102,313 105,190 10,746 487,359 
2001 115 222,773 502,148 8,641 3,392,801 
2002 93 116,864 123,483 6,141 574,895 
2003 62 103,628 111,777 4,339 461,235 
2004 49 66,633 45,819 14,946 182,601 
2005 67 94,264 106,543 4,035 675,738 
2006 125 83,050 90,009 4,710 683,193 
Overall 546 121,713 252,465 4,035 3,392,801 
Std Dev = standard deviation 
Min = minimum 
Max = maximum 
 
 
Table 5.7 Descriptive statistics for total hospital charge by discharge year for MSSA 
 
Discharge year N Mean Std Dev Min Max 
2000 24 68,359 46,113 4,414 180,160 
2001 89 168,224 431,715 9,888 2,957,732 
2002 69 103,714 108,640 10,074 435,997 
2003 27 79,214 65,329 5,260 229,330 
2004 24 76,372 93,130 3,323 397,363 
2005 53 63,210 82,007 7,826 517,451 
2006 98 64,030 79,107 4,324 445,316 
Overall 384 97,307 223,781 3,323 2,957,732 
Std Dev = standard deviation 
Min = minimum 
Max = maximum 
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Figure 5.7 Boxplot of Total Charge by Discharge Year 
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Figure 5.8 Boxplot of Total Charges by Discharge Year with outliers omitted 
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Objective 2: 
Adjusted difference in hospital charge by infection susceptibility 
 
A GLM utilizing a gamma distribution and logarithmic link was used to estimate 
total charge adjusting for potential confounders.  Before a multivariable model could be 
analyzed, each potential covariate was evaluated for inclusion in the model.  Using total 
charge as the dependent variable, the results of the univariate GLMs are available in 
Table 5.8.  Admission source was not considered since data were missing for 219 
patients.   All variables were significant at p-value < 0.25, except for discharge status, 
and thus eligible for inclusion in the multivariable model.  Discharge status was still 
included in the multivariable model since it has been previously established as a known 
confounder.   
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Table 5.8 Univariate analysis (hospital charge = dependent variable) 
 
Variable Coefficient Exponentated Coefficient 
Standard 
Error 
Wald 95% 
Confidence 
Limits 
p-value 
Gender -0.227 0.7969 1.0684 0.7001 0.9073 0.0006 
Discharge 
Status 
0.0413 1.042 1.078 0.899 1.208 0.5838 
Age -0.0033 0.997 1.002 0.992 1.001 0.1464 
DRG weight 0.1596 1.173 1.020 1.129 1.219 <0.0001 
Charlson 
comorbidity 
score 
-0.0548 0.947 1.015 0.920 0.975 0.0002 
Pre-
Infection 
LOS 
0.0428 1.044 1.004 1.036 1.052 <0.0001 
DRG = diagnosis related group 
LOS = length of stay 
 
A propensity score was calculated for the hospital level factors (i.e. bed size, 
urban/rural, teaching status.)  The independent variable was infection susceptibility 
(MRSA or MSSA) and the dependent variables were the hospital level factors.  
Propensity scores were only calculated for 900 patients since 30 patients had missing 
data.  Goodness of fit was assessed using the Hosmer-Lemeshow goodness of fit test (χ2 
= 1.6365, df = 5, p-value = 0.8968).  This indicated good fit.  Balance between the 
MRSA and MSSA groups was reached with respect to the confounders used to calculate 
the propensity score (Table 5.9).  The distribution of propensity scores is below in 
Figures 5.9 and 5.10.   
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Table 5.9 Propensity score by confounders included in the score 
 
      MRSA MSSA 
Bed size   
6 to 99 
100 to 199 
200 to 299 
300 to 499 
500+ 
0.65 0.62 
0.41 0.44 
0.38 0.39 
0.41 0.43 
0.41 0.42 
Urban/Rural Status 
Rural 
Urban 
0.24 0.32 
0.41 0.43 
Teaching Status 
Non-teaching 
Teaching 
0.38 0.39 
0.51 0.51 
MRSA = methicillin-resistant Staphylococcus aureus  
MSSA = methicillin-susceptibile Staphylococcus aureus 
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Figure 5.9 Distribution of propensity scores for MRSA
 
 
Figure 5.10 Distribution of propensity scores for MSSA 
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All variables in Table 5.8 were used in the initial multivariable model as well as 
the calculated propensity score.  Age was then removed from the model since it had a 
multivariable p-value > 0.05.  The results of the multivariable model, excluding age, are 
below in Table 5.10.  The model contained 867 observations. Propensity scores were only 
calculated for 900 observations.  Another 33 observations in the final sample had an 
unavailable discharge status.  In this and all subsequent models the variable susceptibility 
refers to MRSA vs. MSSA. 
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Table 5.10 Multivariable model (hospital charge = dependent variable) 
 
Parameter Coefficient Exponentated Coefficient 
Standard 
Error 
Wald 95% Confidence 
Limits for 
Exponentated 
Coefficent 
p-value 
Susceptibility 0.0512 1.05 1.07 0.93 1.19 0.4277 
Gender -0.2179 0.80 1.06 0.71 0.91 0.0005 
Propensity 
Score 
-0.9575 0.38 1.62 0.15 0.99 0.0479 
DRG weight 0.1135 1.12 1.02 1.08 1.16 <.0001 
Charlson 
comorbidity 
score 
-0.0472 0.95 1.01 0.93 0.98 0.0014 
Pre-infection 
LOS 
0.0413 1.04 1.00 1.03 1.05 <.0001 
Discharge 
Status 
0.1004 1.11 1.07 0.96 1.27 0.1566 
 Log likelihood = -10833.3650, χ2 = 2633, df = 859, n = 867, p-value < 0.0001 
DRG = diagnosis related group 
LOS = length of stay 
 
All two-way interaction effects between infection susceptibility status and the five 
potential modifiers (gender, DRG weight, Charlson comorbidity score, discharge status 
and pre-infection LOS) were assessed by including an interaction term for each in the 
multivariable model.  Likelihood ratio tests were used to compare the full and reduced 
models with different combinations of the interaction terms.  The results are below in 
Table 5.11.  No significant interactions between susceptibility status and discharge status, 
gender or pre-infection LOS were found.  However, there were interactions between 
susceptibility and DRG weight as well as susceptibility and Charlson comorbidity score. 
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Table 5.11 Potential interaction terms with susceptibility (dependent variable = hospital 
charge)  
 
Variable 2LL df Chi-Square p-value 
Main Effects Model -21666.73    
Susceptibility x 
Charlson comorbidity 
score 
-21658.10 1 8.63 0.0033 
Susceptibility x DRG 
weight 
-21646.17 1 11.93 0.0006 
Susceptibility x Gender -21643.33 1 2.84 0.092 
Susceptibility x Pre-
infection LOS 
-21640.54 1 2.79 0.095 
Susceptibility x 
Discharge status 
-21640.20 1 0.34 0.5601 
LL = Log likelihood 
df = degrees of freedom 
DRG = diagnosis related group 
LOS = length of stay 
 
All possible interactions between the Charlson comorbidity score, pre-infection 
LOS, DRG weight, gender and discharge status were assessed using likelihood ratio tests 
as described above.  The interaction terms were tested by adding each one sequentially in 
the model.  There were two significant interactions; DRG weight and pre-infection LOS 
as well as gender and the Charlson comorbidity score.  These interactions were retained 
in the model along with the two associated lower-order terms.   
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Table 5.12 Potential interaction terms among the covariates (dependent variable = 
hospital charge)  
 
Variable 2LL DF Chi-Square P-value 
Main Effects Model -21666.73    
Susceptibility x 
Charlson 
comorbidity score 
-21658.10 1 8.63 0.0033 
Susceptibility x 
DRG weight 
-21646.17 1 11.93 0.0006 
DRG weight x pre-
infection LOS 
-21633.75 1 12.42 0.0004 
Gender x Charlson 
comorbidity score 
-21626.203 1 7.54 0.006 
DRG weight x 
Charlson 
comorbidity score 
-21624.43 1 1.77 0.1835 
DRG weight x 
discharge status 
-21623.51 1 0.92 0.3374 
DRG weight x 
gender 
-21622.72 1 0.79 0.373 
gender x discharge 
status 
-21622.02 1 0.7 0.4038 
Gender x pre-
infection LOS 
-21621.88 1 0.14 0.7066 
Charlson 
comorbidity score x 
pre-infection LOS 
-21621.71 1 0.17 0.6784 
Charlson 
comorbidity score x 
discharge status 
-21621.53 1 0.18 0.6727 
 pre-infection LOS x 
discharge status 
-21621.53 1 0 0.9461 
LL = Log likelihood 
DF = degrees of freedom 
LOS = length of stay 
DRG  = diagnosis related group 
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The final model included susceptibility, gender, the propensity score, DRG 
weight, the Charlson comorbidity score, pre-infection LOS, discharge status, and four 
interaction terms (susceptibility and DRG weight, susceptibility and the Charlson 
comorbidity score, gender and Charlson comorbidity score, and DRG weight and pre-
infection LOS).  The parameter estimates were exponentiated for interpretation (Table 
5.13). No pairwise multicollinearity was found. 
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Table 5.13 Parameter estimates (dependent variable = hospital charge) 
 
Parameter Coefficient Exponentiated Coefficient 
Standard 
Error 
Wald 95% 
Confidence Limits 
of Exponentiated 
Coefficient 
p-value 
Susceptibility 0.4521 1.57 1.11 1.27 1.94 <.0001 
Gender 0.3306 1.39 1.08 1.19 1.62 <.0001 
Propensity 
Score 
0.7105 0.49 1.61 0.19 1.25 0.1372 
DRG weight 0.2487 0.55 1.29 0.33 0.90 0.0174 
Charlson 
comorbidity 
score 
0.0529 0.46 1.24 0.30 0.71 0.0004 
Pre-infection 
LOS 
0.0548 1.06 1.01 1.05 1.07 <.0001 
Discharge 
status 
0.1062 1.11 1.07 0.97 1.27 0.127 
Susceptibility 
x Charlson 
comorbidity 
score 
-0.103 1.11 1.03 1.05 1.18 0.0005 
Susceptibility 
x DRG 
weight 
-0.106 1.11 1.03 1.04 1.19 0.002 
DRG weight 
x pre-
infection LOS 
-0.005 1.00 1.00 0.99 1.00 <.0001 
Gender x 
Charlson 
comorbidity 
score 
-0.079 0.92 1.03 0.87 0.98 0.006 
Log likelihood = -10813.1013, χ2 = 2338, df = 855, n = 867, p-value < 0.0001 
DRG = diagnosis related group 
LOS = length of stay 
81 
 
The deviance residuals were plotted against the fitted values transformed to 
constant information (Figure 5.11).  The transformation to constant information is 
transforming the fitted values to a constant variance scale or constant information of the 
error distribution.  The transformation formula for the gamma distribution is below in 
Equation 5.1.  This scatterplot can be interpreted analogously to a residual by predicted 
plot in linear regression.  Extreme values from Figure 5.11 (highlighted in red) are 
described below in Table 5.14.  Excluding these values from the deviance residuals by 
fitted values plot yielded a random scatter.   
 
Figure 5.11 Deviance residuals by the fitted values transformed to constant information 
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Table 5.14 Extreme values 
 
MRSA  
or  
MSSA 
Gender Age 
Pre-
Infection 
LOS 
Post-
Infection 
LOS 
Discharge 
Year 
Charge 
($) 
MSSA Male 72 8 25 2001 2,909,322.44 
MSSA Male 55 6 19 2001 2,957,731.55 
MRSA Male 67 4 57 2001 3,111,884.28 
MRSA Female 61 18 52 2001 2,993,126.42 
MRSA Male 55 29 95 2001 3,392,801.31 
LOS = length of stay 
 
The above procedures were repeated without the five extreme observations 
(n=925).Variables significant at p-value < 0.25 during univariate analysis were: DRG 
weight, pre-infection LOS and mortality.  Gender was no longer significant and not 
included in the model.  The Charlson comorbidity index was included even though the 
univariate p-value = 0.6430 since severity of illness was a known confounder.  The 
multivariable model included: susceptibility, DRG weight, charlson comorbidity index, 
pre-infection LOS, mortality, and the propensity score.  All two-way interactions with 
infection susceptibility were assessed.  Only the interaction between susceptibility and 
the charlson comorbidity index was significant.  Interactions were assessed between all 
other variables.  The interaction between DRG weight and pre-infection LOS was 
significant.  The final model included susceptibility, the propensity score, DRG weight, 
the Charlson comorbidity score, pre-infection LOS, discharge status, and two interaction 
terms (susceptibility and the Charlson comorbidity score, and DRG weight and pre-
infection LOS).  The parameter estimates were exponentiated for interpretation (Table 
5.15). 
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Table 5.15 Parameter estimates without extreme values (dependent variable = hospital 
charge) 
 
Parameter Coefficient 
Exponentated 
Coefficient 
Standard 
Error 
Wald 95% 
Confidence Limits 
of Exponentiated 
Coefficent 
p-
value 
Susceptibility 0.20 1.23 1.08 1.06 1.42 0.0055
Propensity 
Score 
-0.09 1.10 1.54 0.47 2.56 0.8265
DRG weight 0.13 1.14 1.02 1.09 1.19 <.0001
Charlson 
comorbidity 
score 
0.04 1.04 1.02 1.00 1.09 0.0783
Pre-infection 
LOS 
0.05 1.05 1.00 1.04 1.06 <.0001
Discharge 
Status 
-0.05 0.95 1.06 0.84 1.07 0.4174
Susceptibility 
x Charlson 
comorbidity 
score 
-0.09 0.92 1.03 0.87 0.97 0.0018
DRG weight 
x pre-
infection 
LOS 
-0.003 1.00 1.00 1.00 1.00 0.0004
Log likelihood = -10621.4681, χ2 = 836.06, df = 853, n = 862, p-value =0.7312 
DRG = diagnosis related group 
LOS = length of stay 
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Since susceptibility status was involved in an interaction with the Charlson 
comorbidity score, it must be interpreted in that context.  The median Charlson 
comorbidity score was one and the maximum score was 12.  Higher Charlson scores are 
associated with a higher probability of in-patient death.  Table 5.16 below outlines the 
percent increase/decrease in hospital charge for infection susceptibility taking into 
account the Charlson comorbidity score.  As patients get more severely ill, the total 
charge for MSSA patients increases while the total charge for MRSA patients decreases.  
These results are also displayed in Figure 5.12.  The results of the interaction term DRG 
weight by pre-infection LOS are below in Table 5.17.  As the pre-infection LOS 
increases, the effects of the DRG weight on total charge decrease. 
 
Table 5.16 Change in hospital charge adjusting for Charlson comorbidity score 
Charlson comorbidity score MRSA MSSA 
1 16% 4% 
2 11% 8% 
6 -9% 27% 
12 -33% 62% 
MRSA = methicillin-resistant Staphylococcus aureus 
MSSA = methicillin-susceptible Staphylococcus aureus 
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Table 5.17 Effect modification of DRG weight and pre-infection LOS 
 
DRG weight Pre-infection LOS 
3 6 9 15 
1 1.31 1.39 1.62 2.21 
5 1.92 1.09 1.01 1.00 
10 3.67 1.18 1.02 1.00 
15 7.03 1.29 1.03 1.00 
DRG = diagnosis related group 
LOS = length of stay 
 
Figure 5.12 Change in hospital charge adjusting for Charlson comorbidity score 
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The multivariable model predicted an overall mean charge of $116,404.  The 
MRSA and MSSA mean charges are presented in Table 5.16.  According to the model, a 
case of MRSA bacteremia has an affiliated charge of $22,889 more than a case of MSSA 
bacteremia.     
 
Table 5.18 Predicted charges in US dollars 
 
Overall MRSA MSSA 
Mean 116,404 125,910 103,021 
Standard Deviation 107,898 99,535 117,524 
MRSA = methicillin-resistant Staphylococcus aureus 
MSSA = methicillin-susceptible Staphylococcus aureus 
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Objective 3: 
Adjusted difference in LOS by infection susceptibility 
 
A GLM utilizing a gamma distribution and logarithmic link was used to estimate 
LOS adjusting for potential confounders.  Before a multivariable model could be 
analyzed, each potential covariate was evaluated for inclusion in the model.  Objective 3 
was similar to Objective 2 but used post-infection LOS as the dependent variable in the 
modeling process.  There were 48 observations that had a post-infection LOS equal to 
zero.  Zero is an invalid response value for the gamma distribution.  These observations 
were excluded from this objective.  
 Admission source was not considered since information was missing for 219 
patients.   The five extreme observations identified in Objective 2 were also excluded 
from this analysis.  The results of the univariate GLMs are available in Table 5.19.  All 
variables were significant at p-value < 0.25 except for gender.  Age, DRG weight, 
Charlson comorbidity score, pre-infection LOS and discharge status were all eligible for 
inclusion in the multivariable model.   
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Table 5.19 Univariate analysis (post-infection LOS = dependent variable) 
 
Parameter Coefficient Exponentated Coefficient 
Standard 
Error 
Wald 95% 
Confidence Limits 
of Exponentated 
Coefficent 
p-value 
Gender -0.029 0.97 1.07 0.86 1.10 0.6427 
Age -0.005 1.00 1.00 0.99 1.00 0.0133 
DRG weight 0.086 1.09 1.02 1.06 1.12 <.0001 
Charlson 
comorbidity 
score 
-0.049 0.95 1.02 0.92 0.98 0.0019 
Pre-infection 
LOS 0.009 1.01 1.00 1.00 1.02 0.0083 
Discharge 
Status 0.419 1.52 1.07 1.32 1.75 <.0001 
DRG = diagnosis related group 
LOS = length of stay 
 
The same propensity score calculated above for Objective 2 was used again to 
account for differences in hospital level factors (i.e. bed size, urban/rural, teaching 
status.)  All variables in Table 5.19, excluding gender, were used in the initial 
multivariable model as well as the calculated propensity score.  Age was then removed 
from the model since it had a multivariable p-value >0.05 (p=0.0991).  The results of the 
multivariable model, excluding age, are below in Table 5.20. 
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Table 5.20 Multivariable model (post-infection LOS = dependent variable) 
 
Parameter Coefficient Exponentated Coefficient 
Standard 
Error 
Wald 95% 
Confidence Limits 
of Exponentiated 
Coefficient 
p-value 
Susceptibility 0.10 1.11 1.07 0.97 1.26 0.12 
Propensity 
Score 
1.26 3.54 1.63 1.36 9.19 0.01 
DRG weight 0.07 1.07 1.02 1.04 1.11 <.0001 
Charlson 
comorbidity 
score 
-0.04 0.96 1.02 0.93 1.00 0.03 
Pre-infection 
LOS 
0.01 1.01 1.00 1.00 1.02 0.01 
Discharge 
Status 
0.38 1.47 1.07 1.27 1.69 <.0001 
Log likelihood = -2633.4724, χ2 = 1078, df = 807, n = 814, p-value < 0.0001 
DRG = diagnosis related group 
LOS = length of stay     
 
All two-way interaction effects between infection susceptibility status and the 
four potential modifiers (DRG weight, Charlson comorbidity score, discharge status and 
pre-infection LOS) were assessed by including an interaction term for each in the 
multivariable model.  Likelihood ratio tests were used to compare the full and reduced 
models with different combinations of the interaction terms.  The results are below in 
Table 5.21.  Neither discharge status, DRG weight nor the Charlson comorbidity score 
had significant interactions with susceptibility status.  However, there was a significant 
interaction between susceptibility and pre-infection LOS. 
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Table 5.21 Potential effect modifiers of interaction susceptibility  
 
Variable 2LL DF Chi-Square P-value 
Main Effect Model -5266.9    
Susceptibility x pre-
infection LOS 
-5261.2 1 5.73 0.0167 
Susceptibility x DRG 
weight 
-5260.8 1 0.39 0.5333 
Susceptibility x 
Charlson comorbidity 
score 
-5258.6 1 2.18 0.1395 
Susceptibility x 
discharge status 
-5258.6 1 0.03 0.8684 
LL = Log likelihood 
DF = degrees of freedom 
DRG = diagnosis related group 
LOS = length of stay  
 
All possible interactions between the Charlson comorbidity score, pre-infection 
LOS, DRG weight, and discharge status were assessed using likelihood ratio tests as 
described above.  There was one significant interaction; susceptibility and pre-infection 
LOS. The interaction was retained in the model along with the associated lower-order 
terms.   
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Table 5.22 Identification of interactions (dependent variable = post-infection LOS)  
 
Variable 2LL DF Chi-Square P-value 
Main Effects Model -5266.9    
Susceptibility x pre-
infection LOS 
-5261.2 1 5.73 0.0167 
Charlson comorbidity 
score x pre-infection LOS 
-5255.1 1 6.09 0.0136 
DRG weight x discharge 
status 
-5254.3 1 0.83 0.3625 
Charlson comorbidity 
score x discharge status 
-5253.1 1 1.18 0.2775 
DRG weight x Charlson 
comorbidity score 
-5252.8 1 0.29 0.5934 
Pre-infection LOS x 
discharge status 
-5252.5 1 0.31 0.5806 
LL = Log likelihood 
DF = degrees of freedom 
DRG = diagnosis related groups 
LOS = length of stay 
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The final model included susceptibility, the propensity score, DRG weight, the 
Charlson comorbidity score, pre-infection LOS, discharge status, and two interaction 
terms (susceptibility and pre-infection LOS and pre-infection LOS and Charlson 
comorbidity score).  The parameter estimates were exponentiated for interpretation 
(Table 5.23). Pairwise multicollinearity was assessed.  The only multicollinearity that 
existed was between pre-infection LOS and the interaction term between susceptibility 
and pre-infection LOS.  This collinearity was expected since both terms take into account 
pre-infection LOS.    
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Table 5.23 Parameter estimates (dependent variable = post-infection LOS) 
 
Parameter Coefficient Exponentiated Coefficient 
Standard 
Error 
Wald 95% 
Confidence 
Limits of 
Exponentiated 
Coefficients 
P-value 
Susceptibility -0.05 0.95 1.09 0.80 1.13 0.5715 
Propensity 
Score 
-1.285 3.61 1.62 1.40 9.31 0.0078 
DRG weight 0.0716 1.07 1.02 1.04 1.11 <.0001
Charlson 
comorbidity 
score 
0.0037 1.00 1.02 0.96 1.05 0.8707 
Pre-infection 
LOS 
0.1697 1.18 1.06 1.05 1.33 0.0044 
Discharge 
Status 
0.3625 1.44 1.07 1.25 1.66 <.0001
Susceptibility 
x pre-
infection 
LOS 
-0.021 0.98 1.01 0.96 0.99 0.0091 
Charlson 
comorbidity 
score x pre-
infection 
LOS 
-0.004 1.00 1.00 0.99 1.00 0.0093 
Log likelihood = -2627.5613, χ2 = 832, df = 805, n = 814, p-value = 0.2476 
DRG = diagnosis related groups 
LOS = length of stay 
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There was an interaction between infection susceptibility and pre-infection LOS.  
As pre-infection LOS increased, the post-infection LOS for MSSA patients increased 
more than MRSA patients (Table 5.24).  There was also an interaction between pre-
infection LOS and Charlson comorbidity score (Table 5.25).  Figure 5.13 depicts the 
interaction between susceptibility status and pre-infection LOS.   
 
Table 5.24 Relative increase in post-infection LOS adjusting for pre-infection LOS 
Pre-infection LOS MRSA MSSA 
2 1.28 1.40 
6 2.32 2.77 
9 3.63 4.61 
12 5.66 7.66 
20 18.59 29.78 
LOS = length of stay 
MRSA = methicillin-resistant Staphylococcus aureus 
MSSA = methicillin-susceptible Staphylococcus aureus 
 
Table 5.25 Effect modification of Charlson comorbidity score and pre-infection LOS 
Charlson 
Comobidity 
score 
Pre-infection LOS 
3 6 9 15 
1 1.65 2.74 4.46 11.72 
3 1.01 1.00 1.00 1.00 
6 1.02 1.00 1.00 1.00 
12 1.05 1.00 1.00 1.00 
 LOS = length of stay  
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Figure 5.13 Relative increase in post-infection LOS adjusting for pre-infection LOS 
 
 
 
The multivariable model predicted an overall mean post-infection LOS of 9.86 
days.  The MRSA and MSSA mean post-infection LOSs are presented in Table 5.26.  
According to the model, a case of MRSA bacteremia has an affiliated post-infection LOS 
of 1.30 days more than a case of MSSA bacteremia.   
 
Table 5.26 Predicted post-infection LOS in days 
 
Overall MRSA MSSA 
Mean 9.86 10.40 9.10 
Standard Deviation 4.16 4.99 2.39 
LOS = length of stay 
MRSA = methicillin-resistant Staphylococcus aureus 
MSSA = methicillin-susceptible Staphylococcus aureus 
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 A deviance residual against fitted values transformed to a constant scale plot was 
examined.  As stated in the above objective, this plot can be interpreted similarly to a 
residual by predicted plot in regression.  The points should look randomly scattered.  In 
Figure 5.14, there appeared to be a striped pattern.  No changes were made to the model 
but the model implications will be addressed in the discussion.   
 
Figure 5.14 Deviance residuals by the fitted values transformed to constant information 
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Objective 4: 
Using path analysis to explore the relationship between susceptibility, LOS and total 
hospital charge 
 
PROC CALIS was used to assess the proposed path analysis model in Figure 4.1.  
Post-infection LOS was modeled as an intermediate step and total hospital charges were 
analyzed.  Maximum likelihood estimation for model fitting was used.  The convergence 
criterion was satisfied indicating starting values were successfully calculated by the 
software.  The five extreme observations identified in the previous objectives were 
excluded from this analysis as well (n = 925).  A correlation matrix was calculated to 
verify the association between the variables (Table 5.27).  Post-infection LOS and total 
charge were the most highly correlated variables.   
 
Table 5.27 Correlation matrix 
 
Susceptibility Pre-infection LOS 
Post-infection 
LOS 
Total 
Charge 
Susceptibility 1 
Pre-infection 
LOS 0.1468 1   
Post-infection 
LOS 
0.0598 0.0772 1  
Total Charge 0.1072 0.4234 0.4872 1 
LOS = length of stay 
 
There were two exogenous variables (susceptibility and pre-infection LOS).  They 
were assumed to be correlated.  Therefore, a covariance was modeled and calculated for 
susceptibility and pre-infection LOS.  A covariance between exogenous variables means 
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the variables arose from common causes not modeled in the path diagram.  There were 
two endogenous variables (post-infection LOS and charge) and their variances were also 
modeled.    
 The standardized estimates are below in Table 5.28.  Unstandardized coefficients 
were not calculated since SAS used a correlation matrix for data input.  Also in Table 
5.28 are the R2 values and the proportion of unexplained variance (1-R2) for each 
outcome variable. The proportion of explained variance ranged from 1% for post-
infection LOS to 39% for total charge.   
The variances and covariance for the exogenous variables are in Table 5.29.  The 
variances for susceptibility and pre-infection LOS were one by convention.  This allowed 
SAS to estimate just the variance of the endogenous variables.  (The variances of 
endogenous variables are considered exogenous by definition.)  The covariance between 
susceptibility and pre-infection LOS was 0.14682.  This was the correlation between the 
two variables and can be interpreted similar to a Pearson correlation. 
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Table 5.28 Path Analysis: Regression Coefficients 
 
Outcome Predictors Standardized Coefficient R
2 1-R2 
Post-infection LOS Susceptibility 0.0495 0.01 0.99 
Pre-infection 
LOS 
0.0699   
Total charge Post-infection 
LOS 
0.4573 0.39 0.61 
Pre-infection 
LOS 
0.3881   
LOS = length of stay 
 
Table 5.29 Variances of exogenous variables  
 
Variance Estimate Standard Error 
Susceptibility 1 0.04652 
Pre-infection LOS 1 0.04652 
Post-infection LOS 0.99165 0.04614 
Total charge 0.61286 0.02851 
Covariance 
Susceptibility & Pre-infection LOS 0.14682 0.03325 
LOS = length of stay 
 
 Table 5.30 illustrates the direct, indirect and total effects of each causal variable.  
A direct effect is one variable’s influence on another not taking into account other 
factors.  An indirect effect is one variable’s influence on another through a mediating 
variable.  Total effects are the sum of the direct and indirect effects.[85]  The total effect 
of pre-infection LOS on total charge was 0.42.  The total effect of post-infection LOS on 
charge was 0.46.  Susceptibility only had a 0.02 total effect on charge and a 0.05 total 
effect on post-infection LOS.  Pre-infection LOS had a 0.07 total effect on total charge.  
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Table 5.30 Decomposition of effects  
Endogenous variable 
Causal Variable 
Post-infection 
LOS Total Charge 
Susceptibility 
       Direct effect 0.0495 
       Indirect via post-infection LOS 0.0226 
       Indirect via pre-infection LOS 0.0103 0.05698 
       Total effect 0.0598 0.0796 
Pre-infection LOS 
       Direct effect 0.0699 0.3881 
       Indirect via post-infection LOS 0.032 
       Indirect via susceptibility 0.0073 0.0033 
       Total effect 0.0772 0.4234 
Post-infection LOS 
       Direct effect 0.4573 
       Total effect 0.4573 
LOS = length of stay 
 
Figure 5.15 depicts the standardized estimates within the structural equation 
model.  By convention, the variances of the exogenous variables are not shown in the 
diagram of the path model.   These are the same estimates above in Table 5.28. 
 
101 
 
Figure 5.15 Path Analysis model with standardized estimates 
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The above model had adequate fit (χ2 = 0.8115, df = 1, p-value = 0.3677).  
Because pre-infection LOS, post-infection LOS and charge are all skewed, significance 
tests that take into account non-normal distributions were used.  Other methods to assess 
model fit can be found below in table 5.27.  Specifically, the elliptic correlated chi-square 
and the Bentler and Bonnett’s non-normed index adjust for non-normal distributions.  
Table 5.26 also contains other commonly used significance tests to evaluate goodness of 
fit, their value for this model, and the interpretation of that statistic.[86]  All the statistical 
tests concur that the path analysis model tested had adequate fit. 
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Table 5.31 Path Analysis: Assessment of Fit 
 
Statistical Test Model Statistic Interpretation 
Goodness of Fit Index (GFI) 0.9996 Values close to 0.90 represent a good fit 
GFI Adjusted for Degrees of 
Freedom (AGFI) 0.9956 
Value adjusted for df, with 0.90 a good model 
fit 
Parsimonious GFI  0.1666 Used to compare between models 
Chi-Square 0.8115 
p-value greater than 0.05 indicates good fit Chi-Square DF 1 
p-value > Chi-Square 0.3677 
RMSEA Estimate 0 Values less than 0.05 indicates a good model fit 
Elliptic Corrected Chi-Square 0.3101 p-value greater than 0.05 indicates good fit - 
adjusts for kurtosis p-value > Elliptic Corrected Chi-Square 0.5776 
Bentler & Bonett's Non-
normed Index 1.0024 Value close to 0.9 reflects a good model fit 
.RMSEA = root mean squared error approximation 
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CHAPTER 6 
Discussion 
 
Review of Study Objectives 
There were four general objectives of this investigation.  The crude difference in 
total hospital charges was determined for bacteremias caused by MRSA versus those 
caused by MSSA.  The impact of methicillin resistance in Staphylococcus aureus 
bacteremia was examined separately for dependent variables (1) total hospital charges 
and (2) post-infection LOS while adjusting for confounding.  Finally, the relationships 
between infection susceptibility, LOS, and total hospital charges were examined. 
 
Summary of Findings 
Objective 1 examined the crude difference in total hospital charge.  The overall 
mean hospital charge was $111,636.  The mean charge for MRSA was $121,713 and 
$97,307 for MSSA.  Using the Wilcoxon signed rank test, the difference between the 
total MRSA and MSSA charge was significant.  The median overall charge was $59,764, 
which can be separated into a median MRSA charge of $68,013 and a median MSSA 
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charge of $27,338.  The mean values are at the upper end of the interquartile range which 
affirms the highly skewed nature of charge data. 
According to the multivariable model in Objective 2, the overall mean charge was 
$116,404, which can be divided into $125,910 for MRSA and $103,021 for MSSA.  The 
difference in MRSA charge over MSSA charge was $22,889.  There was an interaction 
between susceptibility and Charlson comorbidity score.  This means that susceptibility 
results must be interpreted in the with respect to the Charlson comorbidity score.  The 
above estimates are for the mean Charlson score of 1.72.  This means the above estimates 
are for the average patient who had a low chance of dying within the year. 
Objective 3 was very similar to Objective 2 except the dependent variable was 
post-infection LOS instead of total charge.  The overall mean LOS was 9.9 day which 
can be broken down into 10.4 and 9.1 days for MRSA and MSSA respectively.  The 
difference was 1.3 days.  The crude post-infection LOS estimates were not significantly 
different.  There was an interaction between susceptibility and pre-infection LOS.  
Therefore, the susceptibility results must be interpreted with pre-infection LOS.  The 
above estimates are for the mean pre-infection LOS of 8.6 days. 
In Objective 4, a path analysis model examined more closely the relationship 
between infection susceptibility, pre-infection LOS and post-infection LOS. The overall 
model fit was good (χ2 = 0.8115, df = 1, p-value = 0.3677).  The model predicted 39% of 
the variability in total charge but only 1% of the variability on post-infection LOS.  The 
standardized direct and indirect effects of each variable were considered.  Susceptibility 
status was not highly correlated with total charge or post-infection LOS.  This implies 
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that susceptibility status may not strongly influence charge or post-infection LOS through 
the proposed model.   
 
Discussion of Results by Objective 
Objective 1 
The crude charges for MRSA and MSSA were $121,713 and $97,307 
respectively.  This represents a mean crude difference of $24,406, which is higher than 
previously reported data.  Most of these investigations reported costs.  As previously 
discussed, charges are known to overestimate actual costs. Mean charges are reported in 
this investigation since economists are interested in means by convention.[32]  
Economists care about means since they can be extrapolated from a sample to the 
population.  However, medians are also reported since it is the measure of central 
tendency that corresponds to skewed data.  
The median overall charge was $59,764, which can be separated into a median 
MRSA charge of $68,013 and a median MSSA charge of $27,338.  The median MRSA 
charge was over twice the median MSSA charge.  Cosgrove et al.[11] reported only a 
1.36-fold increase in median MRSA charge over MSSA. 
 The pilot investigation that analyzed data from one hospital had an overall crude 
median charge of $140,396, which was broken down as $166,901 for MRSA and $86,130 
for MSSA.  These values are over twice the median total charge reported in this 
investigation.  This difference in estimates is substantial.  One possible explanation is that 
the pilot included only patients from a tertiary care facility.  These patients may be more 
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severely ill than patients in other facilities that were included in this investigation.  
Another possible reason for the increased charge from the pilot investigation stems from 
the study period.  This investigation adjusted total charge to 2006 dollars while the pilot 
included 2007 values.  Inflating this investigation’s total charges to 2007 dollars would 
increase the estimates, but not enough to account for the entire charge disparity.  
However, both investigations indicate that MRSA bacteremias are more expensive than 
MSSA bacteremias.  
 It was intended to use repeated measures ANOVA to examine trends in hospital 
charge over the study period.  However, only four hospitals had data for every study year.  
SAS used only these four hospitals to calculate the repeated measures ANOVA.  
Extrapolating these results to the entire study population would be inappropriate.  Instead 
the data were examined descriptively; 2001 was the only year that seemed drastically 
different.  This was due to five extreme observations that were excluded from the 
analysis during objective two.  (See Objective 2 for a more complete discussion of the 
extreme observations.)   
A post-hoc analysis was performed using a generalized estimating equations 
(GEE) approach to compare total hospital charge over the study period while accounting 
for the hospital groupings within the dataset.  The GEE model used a gamma distribution 
and log link.  No difference was seen in total charge per year during the study period.  An 
interaction term was used to test whether there was a difference in MRSA vs. MSSA total 
charge throughout the study period.  No difference was found.  Therefore, it can be 
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concluded that the total charges and the total charges for MRSA and MSSA were not 
statistically different during each year of the investigation.   
 
 Objective 2 
 A multivariable model was used to determine the role susceptibility played on 
total hospital charges.  Along with potential confounders, a propensity score was included 
in the model as a way to account for hospital differences (e.g., teaching status, bed size, 
and urban/rural).  A recent meta-analysis identified key components necessary for any 
investigation using propensity scores.[87]  Important components included sufficient 
events per variable (EPV), continuous variable conformity with linear gradient, 
interactions, collinearity, assessment of model fit, discrimination of the model, balance 
achieved between the confounders, and adjustment methodology.  In a logistic model, 
there need to be at least 10 observations per variable.[88-90]  This rule of thumb has also 
been generalized to propensity scores to assure sufficient EPV.  This investigation used 
only 3 variables for more than 900 observations.  Continuous variable conformity relates 
to continuous variables used to create the propensity score.  All the variables used to 
create the propensity score were categorical.  Therefore, it was not possible to evaluate 
collinearity.  Fit was assessed using the Hosmer-Lemeshow goodness of fit statistic.  A 
non-significant p-value was obtained indicating a lack of evidence suggesting the model 
did not fit the data well.  Assessment of fit relates closely to balance between the 
treatment groups.  The MRSA and MSSA groups appeared to be balanced by the 
variables used to calculate the propensity score (Table 5.9).   Propensity scores from a 
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poorly fit model and without balance between the treatment groups could lead to biased 
estimates of treatment effect.  The propensity score used in this analysis had adequate fit 
and was balanced between the treatment groups. 
 Propensity scores can either be used as continuous variables or stratified into 
quintiles.  Since there was a lot of overlap between the MRSA and MSSA groups with 
respect to propensity scores, the scores were used as a continuous variable in the second 
stage regression model.  In a post hoc fashion, propensity score quintiles were run with 
the final multivariable model.  Less than a 1% change occurred in the susceptibility 
parameter estimate.  This indicates using the propensity score as a linear variable was not 
inappropriate.  Of note, when the observations were separated into quintiles based on 
propensity score, it was observed that no observations existed in the 3rd quintile.  
Although unusual, this was thought to be a function of the cluster distribution of scores.  
Most likely this was caused by the propensity score being composed entirely of 
categorical variables with few categories.    
After the model was initially fit, an analysis of residuals was conducted.  Residual 
analysis is used in regression to identify a model specification problem or 
nonhomogeneous variance.[91]  For the gamma distribution, it is recommended that 
deviance residuals be plotted against the fitted values transformed to the constant 
scale.[92]  This plot should look like a random splatter of points.  There were five 
observations that stood out from the rest as extreme (Figure 5.11). 
 Extreme values identified by the deviance residual plot were examined more 
closely.  They were a mixture of MRSA and MSSA observations all from the same 
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hospital and same study year (2001).  Removing all data points from that hospital was 
considered but there were many observations from various study years that were not 
extreme.  Leaving the five observations in the dataset was also considered.  As previously 
discussed, the charge data was expected to have a long right tail.  Having a handful of 
large charge data points was anticipated.  But, the magnitude of the five extreme 
observations was astronomical.  It was decided to remove these five observations for the 
remainder of the analysis.  The model was re-run excluding these observations.   
Adjusting for confounders, the overall mean charge was $116,404, which can be 
divided into $125,910 for MRSA and $103,021 for MSSA.  The difference in MRSA 
charge over MSSA charge was $22,889.   These estimates adjusted for propensity score, 
DRG weight, the Charlson comorbidity score, pre-infection LOS, discharge status and the 
interaction between susceptibility and the Charlson comorbidity score as well as the 
interaction between DRG weight and pre-infection LOS.   
Since susceptibility status was involved in an interaction with the Charlson 
comorbidity score, it must be interpreted in that context.  The median Charlson 
comorbidity score was one and the maximum score was 12.  The interquartile range was 
from 0 to 2. As a reminder, higher Charlson scores are associated with a higher 
probability of in-patient death.  Figure 5.12 graphically depicts the relationship between 
susceptibility status and the Charlson comorbidity score.  For most patients (Charlson 
comorbidity score 0 to 2) MRSA bacteremias have a higher total charge than MSSA 
bacteremias.  But as the Charlson comorbidity score increases, the total charge for MSSA 
infections increases while the total charge for MRSA infections decreases.  One possible 
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explanation is that MRSA patients may be expiring pre-maturely in the hospital causing 
them to have a truncated charge. 
There was also an interaction between DRG weight and pre-infection LOS (Table 
5.17).  Interpretation of this interaction showed that as pre-infection LOS increased, the 
total charge was less dependent on the DRG weight.  For example, a patient with a pre-
infection LOS of three days had highly variable charges depending on DRG weight. (A 
higher DRG weight had a higher total charge.)  But the effects of DRG weight 
diminished as pre-infection LOS increased.  Since DRG weight was one method that 
controlled for severity of illness it can be suggested that severity of illness was less 
important to total hospital charge as pre-infection LOS increased. 
  
Objective 3 
Objective 2 demonstrated that pre-infection LOS was more influential on total 
charge as it increased than severity of illness.  Susceptibility status was examined to see if 
it could predict post-infection LOS similarly to total charge.  The same main effects were 
used in the LOS multivariable model as the model with total charge as the outcome 
variable.   Although the main effect of susceptibility status was not significant in the 
multivariable model, there was a significant interaction with pre-infection LOS.  For 
MRSA and MSSA patients the post-infection LOS increased as pre-infection LOS 
increased but, the post-infection LOS increased more for MSSA patients than MRSA 
patients as pre-infection LOS increased. The mean post-infection LOS for MRSA 
patients was not much different than for the MSSA bacteremia patients.  However, a 
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difference in post-infection LOS becomes apparent as pre-infection LOS increases 
(Figure 5.13).   
There was also an interaction between pre-infection LOS and the Charlson 
comorbidity score (Table 5.24).  As the Charlson comorbidity score increased, the effect 
of pre-infection LOS decreased.  The median Charlson score was 1 (IQR = 0 to 2).  For 
most patients, pre-infection LOS has a large impact on post-infection LOS.  But for 
patients whose Charlson score was outside the IQR, pre-infection LOS does not have 
much effect on post-infection LOS. 
The multivariable model adjusted for the propensity score, DRG weight, the 
Charlson comorbidity score, pre-infection LOS, discharge status and the interaction 
between susceptibility and pre-infection LOS as well as the interaction between Charlson 
comorbidity score and pre-infection LOS.  The overall mean LOS was 9.86 day, which 
can be broken down into 10.4 and 9.1 days for MRSA and MSSA respectively.  The 
difference was 1.3 days.  These estimates are for the mean pre-infection LOS of 8.59 
days. 
After the multivariable model was calculated, an analysis of residuals was 
conducted.  The deviance by residual plot could have looked better (Figure 5.14).  There 
appeared to be a stripped pattern.  This could indicate model misspecification or 
nonhomogeneous variance.  Most likely the problem related to the distribution and link 
functions used for the model.  A logarithmic transformation of the data did not make 
post-infection LOS look “normal.” It has been suggested that the Inverse Gaussian 
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distribution, with a high initial peak and long right tail may be more appropriate for LOS 
data.[93]  Different distributions and link functions were not explored.    
 
Objective 4 
 Based on the results from Objectives 2 and 3, the question then becomes whether 
the increase in total hospital charge for MRSA bacteremia patients is purely a function of 
LOS.  Path analysis was used to evaluate the joint effects of susceptibility, pre-infection 
LOS, post-infection LOS and charge.  The standardized regression coefficients can be 
interpreted as correlation coefficients.[82]  Susceptibility status had a direct effect of 
0.0485 on post-infection LOS and an indirect effect on total charge of 0.0226.  Pre-
infection LOS had a direct effect on post-infection LOS of 0.0699.  Pre-infection LOS 
had a direct effect of 0.3881 on charge and an indirect effect of 0.032 through post-
infection LOS for a total effect of 0.4201.  Post-infection LOS had a direct effect on 
charge of 0.4573. 
 Standardized path coefficients with an absolute value less than 0.10 are 
considered to have a small effect.  Values around 0.30 have a medium effect and values 
greater than 0.5 are considered to have a large effect. [94]  The path between 
susceptibility and post-infection LOS and the path between pre-infection LOS and post-
infection LOS both have small effects.  This implies that the susceptibility status (MRSA 
vs. MSSA) had little impact on post-infection LOS or total charge. The path from post-
infection LOS to total charge had a large effect.  Also, the total effect of pre-infection 
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LOS on charge was medium to large.  This suggests (as Objectives 2 and 3 indicated) that 
pre-infection and post-infection LOS have a large impact on total charge. 
SAS output produced only standardized results.  The biggest advantage of 
standardized results is that they can be directly compared across variables.  
Unfortunately, by standardizing the regression coefficients the results lose their original 
units.  Unstandardized results yield estimates in their original metrics but cannot be 
directly compared across variables.  SAS does not produce unstandardized estimates 
because the path analysis input was based on the correlation matrix.  Since the input (the 
correlation matrix) is already standardized, unstandarized estimates cannot be produced. 
Epidemiologists are most often concerned with the magnitude of association where 
unstandardized estimates are preferred.[82]  However, this analysis was designed to 
estimate how much each variable contributed to the other variables in the model.  In this 
case, interpretation of standardized regression coefficients was appropriate. 
 Like other statistical techniques, path analysis relies on certain assumptions.  SAS 
used maximum likelihood estimation to calculate the regression coefficients.  This 
technique requires the data to be normally distributed.  Transformation of the data was 
considered.  Although a logarithmic transformation made the charge data normal, it did 
not have the same effect on LOS.  Another approach, which was executed, was to move 
forward with the non-normally distributed but carefully consider the implications on the 
model.  First, the parameter estimates could be biased.  With a large sample size, 
however,  parameter estimates are assumed to be fairly accurate.[94]  The bigger problem 
is that significance tests tend to be significant too often.  Put another way, the true model 
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may be rejected too frequently (Type I error).[95]  The significance testing problem was 
addressed by using corrected test statistics such as the elliptic correlated chi-square.  If 
the goodness-of-fit tests had indicated poor fit, this would have meant the model did not 
explain the associated correlation well.  
 Another problem with this analysis is the independence assumption.  Path analysis 
assumes independence. However, the observations in this analysis came from different 
hospitals.  Patients within the same hospital are not independent.  Previous research 
indicates that having dependent data leads to goodness-of-fit tests that are too 
conservative.  In the same investigation it was noted that the parameter estimates appear 
minimally biased despite their dependence.[96]  
 As previously discussed, the last step of path analysis is to manipulate the model.  
The fit was good, so this model was not manipulated.  One possibility would have been to 
trim the model.  Small effect path coefficients can be essentially removed from the model 
and the model can be evaluated.  Susceptibility had the smallest effect and would be the 
first variable trimmed from the model.  This implies that having a MRSA vs. a MSSA 
bacteremia had a small impact total charge.     
The model accounted for 39% of the variability in total hospital charge and it 
accounted for only 1% of the variability on post-infection LOS.  Although the model fit 
was good, much of the variability in charge and post-infection LOS was unexplained.  
This implies the absence of important factors in the relationship between charge, 
susceptibility and LOS.  The two most obvious factors that were missing are severity of 
illness and discharge status/mortality.  Including these factors would probably have 
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accounted for more variability.  Also, including these confounders may have changed the 
correlation coefficient between susceptibility status and post-infection LOS and total 
charge.  Future path models should include these confounders.   
  Path analysis allows for the testing of structural models developed based on a 
priori assumptions about the direct and indirect relationship between variables.  
However, the structural model being tested must be based on theoretical assumptions.  
The model assumed susceptibility status had an effect on total charge.  The model was 
not rejected but this does not prove that having MRSA vs. MSSA leads to higher charges.  
Failure to reject a path model does not prove that it is correct. 
 
Practical Implications 
 This investigation confirms previous single-center analyses that reported MRSA 
bacteremia is more expensive than MSSA bacteremia.  These results were found in both 
the crude analysis and the multivariable model.  The multivariable model controlled for 
known confounders (i.e., DRG weight, Charlson comorbidity score, discharge status, pre-
infection LOS and hospital level factors).  While controlling for confounders, the 
predicted hospital charge was still higher for MRSA than MSSA.   
Why would MRSA bacteremias be associated with higher total charges as 
compared to MSSA bacteremias?  As previously discussed several single center reports 
have reported MRSA bacteremia being associated with a higher cost/charge than MSSA 
bacteremia.  There are several possible explanations for this phenomenon: MRSA and 
MSSA patients are different, the MRSA and MSSA organisms are different, or their 
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treatments have very different charges.  These three possibilities are discussed more fully 
in the following paragraphs. 
The most obvious difference between MRSA and MSSA patients is severity of 
illness.  Although this investigation attempted to control for severity of illness using the 
Charlson comorbidity score and DRG weights, there may still have been uncontrolled 
disparity in patients underlying disease status.  For example, a patient with endocarditis is 
not necessarily comparable to a patient with a simple bacteremia.  The patient with 
endocarditis will most likely be sicker and require more resources.  However, the use of 
DRG weights should help control for this dissimilarity since the patient with endocarditis 
should have a higher relative weight.  
Another potential explanation is that the MRSA and MSSA organisms are 
different.  The inequality in total hospital charge could be that MRSA is more virulent 
than MSSA.  If MRSA bacteremia were more virulent, these patients would require 
longer hospitalizations and more resources.  This would make their hospital stays more 
expensive.  However, there is currently no evidence in the literature to suggest that 
hospital-onset MRSA infections are more virulent than their MSSA counterparts.[97, 98]  
Host differences are not thought to be the cause of charge disparity. 
Alternatively, MRSA and MSSA bacteremia patients may have different 
treatments factors, which cause MRSA bacteremia patients to have a higher total charge.  
These factors include (1) decreased effectiveness of pharmacologic treatment (2) a delay 
in effective treatment while waiting for microbiologically effective antimicrobials (3) an 
increased need for surgery or other procedures.  Vancomycin has been the drug of choice 
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for treating MRSA bacteremia.  However, vancomycin has shown to have decreased 
effectiveness in treating MRSA bacteremia.[99]  Newer antibiotics are available (e.g., 
quinupristin–dalfopristin, linezolid, daptomycin and tigecycline) but there are limited 
data regarding their efficacy as compared to vancomycin in treating MRSA 
infections.[100]  Lodise et al. found that delayed treatment was associated with a longer 
duration of hospitalization (20 vs. 14 days, p-value = 0.05).[101]  This is important since 
previous investigations have reported that roughly 35% of patients with MRSA 
bacteremia do not receive appropriate empiric therapy.[102, 103]  MRSA patients also 
have an increased need for surgery and other procedures resulting from the resistant 
infection.[55]  However, the use of DRG weights should account for differences in 
surgeries and procedures as long as the complication was severe enough to merit a DRG. 
The exception to this would be procedures not captured by an individual DRG.  For 
example, vancomycin requires blood levels to be taken to monitor the drug’s trough 
concentrations.  Repeated blood levels are an extra charge that MSSA patients would not 
incur.  There is not a DRG for blood draws.  Additional surgeries should be accounted for 
by DRG weight but minor procedures may not, which could result in a discrepancy of 
total charge.    
Another consideration about treatment differences relates to inter-hospital 
variability.  Although guidelines advise standards of care, different hospitals have their 
own standard operating procedures.  For example, researchers at Duke Medical Center 
recommend using transesophageal echocardiography (TEE) to determine the length of 
treatment for uncomplicated catheter-associated Staphylococcus aureus bacteremia.[104]  
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This diagnostic step is not universally practiced to determine duration of treatment.  Also, 
different hospitals have different infection control policies.[4]  Even within a hospital, 
infection control policies may have changed during the study period.  The impact of 
inter- and intra-hospital variability should be minimal since there was not a significant 
difference in total charge (overall or by susceptibility status) over the study period as 
evidenced by the GEE model.  
 From a hospital administrator’s perspective, the results of this investigation are 
important.  The increased total charge for MRSA vs. MSSA bacteremia was roughly 
$23,000 per case.  Charges are known to over-inflate costs; a conservative increase of 
hospital cost could be approximated at $11,000 per case.  If a hospital had 100 MRSA 
bacteremias per year, this represents an additional $1,100,000 spent on MRSA 
bacteremias.  The cost of an infection control program can be compared to this figure.  If 
an infection control program costs $500,000, the hospital would have a net savings.  If 
the infection control program costs $1,200,00, more factors may need to be considered.  
When considering whether to spend hospital resources on an infection control program, 
the cost of the program must be weighed against the potential savings of preventing a 
resistant infection.   
Furthermore, the argument has been made that the calculated “cost of resistance” 
underestimates the true burden of resistance.[105]  Additional costs may include home 
intravenous therapy, an extended care facility and/or costs of rehabilitation.[106]  
Providing outpatient intravenous therapy would involve the medication costs, nursing 
time, supplies, laboratory tests, intravenous line placement and management. Since this 
120 
 
study was conducted from the hospital’s perspective, the additional cost of managing 
MRSA vs. MSSA bacteremia outside of the hospital was not considered.   
The effects of mortality on total charge merit further discussion.  In this 
investigation the 30.8% of MRSA bacteremia patients expired in the hospital as 
compared to 21.4% of MSSA patients (χ2 = 11.92, df = 2, p-value = 0.0026).  A meta-
analysis demonstrated a significant increase in mortality associated with MRSA 
bacteremia relative to MSSA bacteremia (OR = 1.93, p-value < 0.001).[20]  However 
increased mortality could either increase or decrease total hospital charge.  If the patient 
died sooner the hospital stay charge would be truncated.  However, the patient could have 
complications prior to death which would lengthen the hospital stay.  A drawn out 
hospital stay ending in death could increase total charge, especially if significant 
treatments and procedures were conducted surrounding the end-of-life period.  Since this 
investigation had a large sample size, the overall effects of extended and truncated LOS 
was assumed to be minimal. 
 The results of this study should have good external validity.  This was a multi-
hospital investigation that included hospitals of various size and teaching status.  
However, the study population was refined to make the MRSA and MSSA groups as 
similar as possible with respect to known confounders.  The purpose of this data 
manipulation was to isolate the effect of infection susceptibility on total charge and post-
infection LOS.  By excluding outliers the generalizability does decrease.  These 
exclusions were necessary to maximize internal validity.  For example, MRSA patients 
with pre-infection LOS longer than 62 days were excluded from the analysis.  These data 
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points were not excluded because they were believed to be erroneous.  They were 
excluded because MRSA patients had a pre-infection LOS only this long (except for 1 
MSSA patient.)  In reality, patients do have pre-infection LOSs longer than 62 days 
before contracting MRSA.  Excluding these patients illustrates the trade-off between 
internal and external validity.  However, the effects of excluding these patients should 
bias the results toward the null.  Since a significant difference was found between total 
charges, including these patients would have made the difference in charge greater.  By 
decreasing the pre-infection LOS for the MRSA group, the difference in overall total 
charge was conservative. 
 
Limitations 
Admittedly, there were limitations to this investigation.  Different hospitals have 
varying infection control policies, formularies/protocols, and/or provide dissimilar levels 
of additional education regarding proper selection of initial antibiotic therapy.  This was a 
limitation since the costs of these programs would affect each hospital’s total charges 
differently.  Additionally, the incidence of MRSA infections can be reduced substantially 
through prevention.[62]  The role of infection control was not addressed since that 
information was not available within the Cerner HealthFacts data warehouse.  Hospital 
level factors were used in an attempt to control for inter-hospital variability. 
This analysis was based on two fundamental assumptions.  First, the charges prior 
to infection onset were comparable between the MRSA and MSSA groups.  Only one 
charge was provided for the entire hospitalization.  Charges were not available as pre- 
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and post-infection charges.  Differences in pre-infection charges could bias the study 
results.  Specifically, the difference in total hospital charge would be overestimated if 
pre-infection charges were higher in the MRSA group.  The difference would be 
underestimated if the pre-infection charges were higher in the MSSA group.  Second, the 
charges are assumed to be a result of MRSA or MSSA bacteremia.  Hospital charges 
unrelated to the bacteremia that were unequal between the groups could introduce bias 
into the investigation and also inflate the difference in hospital charges between the 
MRSA and MSSA and overestimate charge.  There is no way to discern which charges 
relate to the bacteremia from the aggregate total charge provided for this analysis.  
However, controlling for severity of illness should help account for differences between 
the MRSA and MSSA groups.  It was assumed that all differences in post-infection 
charge were attributed to the bacteremia.  Given the study design, this limitation was 
unavoidable.      
Previous methods for calculating the economic burden of resistance have varied 
largely.  Many single center investigations were able to collect actual cost from their 
institution.[12, 14, 15]  Another investigation was able to identify only costs associated 
with the SAB.[16]  And one of these investigations was able to collect costs attributable 
to SAB after hospital discharge.[16]  Charges were not able to be sub-categorized in the 
current study.   Only an overall aggregate charge was available for each subject since the 
data came from a large multi-hospital database.   
The pilot investigation included transferred patients in the patient population.  
However, transferred patients were excluded in this investigation.  In both investigations 
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there was no way to know the duration of hospitalization before the transfer.  Including 
these patients could lead to the inclusion of non-nosocomial infections.  Excluding 
transferred patients could underestimate the number of actual cases.  Since the pilot 
included only a tertiary care facility it was assumed that patients transferred there had 
been at another facility previously.  This investigation included all types of hospitals.  
Therefore, it seemed more appropriate to exclude transferred patients.  This means that 
potential cases may have been excluded. The effects of excluding these patients were 
thought to be minimal since only 55 MRSA and 19 MSSA patients were transferred from 
another facility.   
 Three data manipulation steps led to the exclusion of potential patients.  First, 
several hospitals’ data were excluded when the Micro and Large datasets were merged.  
This was most likely a result of hospitals subscribing to different Cerner services -- an 
unavoidable circumstance that resulted in a smaller sample size.  Cerner is a for-profit 
company that provides information technology services to its clients.  Each client 
customizes the services it contracts for through Cerner which means that not all hospitals 
manage the same data elements within their system.  Second, only 2006 DRG codes were 
used.  This was done for consistency since all charges were inflated to their 2006 value.  
Unfortunately, 122 observations were discarded.  Almost all of them were surgical 
DRGs.  When DRGs are updated, their weights change.  For the purposes of this project, 
all the weights needed to be consistent.  Third, patients with charges less than $11,896 
and a LOS greater than nine days were excluded.  It became obvious from looking at the 
data that some observations were erroneous.  Some charges were too low based on the 
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total LOS.  The pilot investigation has a minimum charge of $11,896.  Any observation 
with a total charge lower than this was excluded.  In the pilot investigation, the median 
pre-infection LOS for MRSA was 10 days.  A LOS greater that nine days should have a 
total hospital charge greater than the minimum which was $11,896; therefore, any charge 
less than $11,896 with a LOS greater than 9 days was excluded.  This data manipulation 
step excluded patients with extremely low charges and a long LOS. 
Adjusting for underlying severity of illness was a major concern in this 
investigation.  There is currently no one well-validated, universally accepted illness 
severity score for infectious disease outcomes.[27]  One investigation did explore a 
comorbidity risk-adjustment measure specifically for MRSA.[39]  However, this measure 
has not been widely used in the literature. Another investigation comparing two severity 
of illness indices created for non-infectious disease related indications, the Charlson 
comorbidity score and the Chronic Disease Score, found both to be indicators of 
increased risk for a nosocomial infection based on preexisting comorbidities.[107] Other 
investigations have used a variety of techniques including APACHE score [12, 18], 
McCabe/Jackson score [11] and the Charlson comorbidity score.[60]  The APACHE 
score is intended for use with ICU patients while the McCabe/Jackson score has been 
evaluated for non-ICU patients.  DRGs have been used as a surrogate for severity of 
underlying illness in MRSA bacteremia.[13]  This approach was originally developed to 
accurately assess the cost of hospitalization by adjusting for severity of illness within the 
DRG classification scheme.[46, 47]  This investigation used both DRG weights and the 
Charlson comorbidity score to adjust for severity of underlying illness.  However, it 
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should be mentioned that the Charlson comorbidity score might not have been the ideal 
method for controlling comorbid conditions.  The adapted Charlson comorbidity score 
uses ICD-9-CM information, which is based on discharge data. Therefore, additional 
comorbidities that arose after the onset of infection would be intermediaries between 
infection susceptibility and charge, thereby potentially biasing the study results.[107]       
This investigation did not assess the appropriateness of a patient’s antibiotic 
therapy.  One previous investigation found that 32.9% of patients with a MRSA 
bacteremia did not initially receive appropriate antibiotic therapy.[102]  As previously 
discussed, charges are higher for patients who have delayed initiation of appropriate 
therapy.[108]  Additionally, differences in antibiotics play a role in patient outcomes for 
MRSA and MSSA infections.[109]  For example, whether an antibiotic is bacteriostatic 
or bacteriocidal could change the effectiveness and duration of treatment.  Although 
researchers are beginning to question the effectiveness of vancomycin for treating MRSA 
bacteremia,[99] this investigation did not evaluate the efficacy of vancomycin. 
Pharmacotherapy information was not included in the data provided by Cerner.   
This investigation did not examine any patient clinical sub-populations in the 
multivariable analysis.  Staphylococcus aureus infections are a serious and frequent 
complication of hemodialysis.[110]  Two reports have been published specifically 
evaluating the economic impact of SAB in end-stage renal disease patients undergoing 
hemodialysis.[15, 16]  This investigation deliberately did not focus on any particular 
diagnosis sub-populations in an attempt to increase external validity. 
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 Finally, this study relied on previously collected data.  Retrospective data can be 
convenient since the researcher does not have to wait for the data to be prospectively 
collected.  However, records must be complete and accurate or the results could be 
biased.[61]  The final sample for this investigation was complete.  However, many 
potential observations were excluded from the sample because their data were not 
complete.  The advantage of the database used was the size.  Even though many 
observations were removed, the final sample was still large. 
 
Future Research 
Future research in this area should be focused on path analysis.  Path analysis is 
ideal for modeling an exposure, confounders, intermediaries and outcomes 
simultaneously.  This method is a suitable technique to tease out why MRSA infections 
seem to cost more than MSSA infections.  However, this technique requires much 
forethought.  The model is only as good as the a priori assumptions it is based on.  
Developing a more complete path analysis model that includes all potential confounders 
as well as post-infection LOS would be helpful.  The model from this analysis suggests 
the impact of susceptibility status on total charge was small.  Creating a more 
comprehensive path model would either support or refute this finding.  Severity of illness 
and mortality should be added to the model.   This investigation should serve as a 
baseline of comparison for future path analysis models.   
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Conclusions 
The broad purpose of this investigation was to explore the relationships between 
susceptibility status (MRSA vs. MSSA), total hospital charge and LOS (pre- and post-
infection).  MRSA was associated with a $24,406 increase in total hospital charge.  A 
multivariable model took into account potential confounders and estimated a $22,889 
adjusted increase.  However, the multivariable indicated that the effect of infection 
susceptibility was different based on the Charlson comorbidity score.  For the majority of 
patients, MRSA had higher total charges.  But, as patients became more severely ill, 
MRSA charges decreased while MSSA charges increased.   
In the multivariable model with post-infection LOS as the outcome, the model 
predicted a mean post-infection LOS increase of 1.3 days for MRSA over MSSA 
patients.  However, the magnitude of increased post-infection LOS based on pre-infection 
LOS was different for MRSA and MSSA patients.  For the majority of patients, there was 
no difference in post-infection LOS based on susceptibility.  But as pre-infection LOS 
increased, post-infection LOS for MSSA patients became notably longer than MRSA 
patients.   
Path analysis incorporated all the variables of interest in one model.  
Susceptibility status was not highly correlated with total charge or post-infection LOS.  
This implies that susceptibility status may not highly influence charge or post-infection 
LOS through the proposed model.  However, two important confounders were not 
included in the analysis (severity of illness and mortality).  Future research should 
incorporate these confounders in the structural equation models.  The role of 
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susceptibility status may still have an indirect effect on total charge or post-infection LOS 
through confounders not included in this investigations path analysis. 
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Appendix B 
Codebook for Categorical Variables 
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Variable Collected Variable Categories  
            & Subcategories 
Variable Name Variable Code 
Susceptibility MRSA  
MSSA 
susceptibility MRSA = 1 
MSSA = 0 
Gender Gender gender1 Male = 1  
Female = 0 
Admission Source Referral admission_source Referral =1 
Physician referral   
Clinic referral   
HMO referral   
Transfer  Transfer = 2 
Transfer from a hospital   
Transfer from a skilled nursing facility 
(SNF) 
  
Transfer from another health care 
facility 
  
Emergency Room  Emergency Room = 7 
N/A  N/A = 3 
Not available   
Null   
Not mapped   
(continued) 
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Appendix B: (continued) 
 
Variable 
Collected 
Variable Categories  
            & Subcategories 
Variable Name Variable Code
Status at 
Discharge 
Discharged Home discharge Discharged 
Home = 1 Discharged to home  
Discharged/transferred to home under care of Home IV provider  
Discharged/transferred to home with home health service   
Transferred   Transferred = 2 
Discharged/transferred to another short term hospital   
 Discharged/transferred to SNF   
 Discharged/transferred to ICF   
 Discharged/transferred to another type of inpatient care institution   
 Discharged/transferred to another rehabilitation facility   
 Discharged/transferred to a long term care hospital   
 Hospice  Hospice = 6 
 Hospice / home   
 Hospice / medical facility   
 Expired  Expired = 3 
 Other  Other = 4 
 Left AMA   
 Still patient or expected to return for outpatient services   
 Discharged/transferred within this institution to Medicare 
approved swing bed 
  
 N/A  N/A = 5 
 NULL   
 Not Mapped   
(continued) 
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Appendix B: (continued) 
 
Variable Collected Variable Categories  
            & Subcategories 
Variable Name Variable Code 
Discharge Status Discharged 
Expired 
N/A 
mortality Discharged = 1  
Expired = 0 
N/A=2 
Type of Payer Insured payer Insured = 1 
 BCBS   
 Other Commercial Payer   
 Other Government   
 Other Non-govt   
 Self-Insured   
 CHAMPUS (military dependents)   
 HMO/Managed care   
 Worker's Compensation   
 Medicare  Medicare = 5 
 Medicaid  Medicaid = 4 
 Self Pay  Self Pay = 2 
 N/A  N/A = 5 
 Unknown/Missing/Invalid   
 Null   
 Not mapped   
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Appendix C 
Codebook for Continuous Variables 
 
 
 
 
Variable Collected Unit of Measurement Variable Code 
Age year age 
DRG weight n/a weights 
Charlson comorbidity score n/a charlson 
Propensity score n/a prob 
Total hospital charge dollars charge 
Total length of stay day total_LOS 
Pre-infection LOS day pre_infection_LOS 
Post-infection LOS day post_infection_LOS 
DRG = diagnosis related group 
LOS = length of stay 
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Appendix D 
SAS Code 
 
*Entire SAS code; 
libname phd 'C:\Documents and Settings\Suzanne Phillips\Desktop\SAS PhD 
files'; 
run; 
 
libname phdfinal 'C:\Documents and Settings\Suzanne Phillips\My 
Documents\PhD'; 
run; 
 
*Micro data; 
PROC IMPORT OUT= phd.phdmicro  
            DATAFILE= "C:\Documents and Settings\Suzanne 
Phillips\Deskto 
p\Suzanne_MRSA\all_criteria_ms_sep1.txt"  
            DBMS=DLM REPLACE; 
     DELIMITER='7C'x;  
     GETNAMES=YES; 
     DATAROW=2;  
RUN; 
 
ods html file = "phd.phdmicro"; 
libname phd 'C:\Documents and Settings\Suzanne Phillips\Desktop\SAS PhD 
files'; 
proc print data=phd.phdmicro; 
format id comma30.0; 
run; 
ods html close; 
 
data phd.phdmicro1; 
 set phd.phdmicro; 
 format id comma31.0; 
 format SUSCEPTIBILITY comma3.0; 
 format microbial_code comma5.0; 
run; 
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*micro results with all observations; 
proc freq data=phd.phdmicro1; 
 tables susceptibility; 
 run; 
 
Proc sort data = phd.phdmicro1; 
 by id; 
 run; 
 
proc freq data = phd.phdmicro1 noprint; 
 table id / out=phd.phdmicro1__1; 
 run;  
 
 
*remove observations if susceptibility = 2,3,4,10,11; 
data phd.phdmicro2; 
 set phd.phdmicro1; 
 if SUSCEPTIBILITY <7 then delete; 
 if SUSCEPTIBILITY > 9 then delete; 
 run; 
 
proc sort data=phd.phdmicro2; 
 by id ascending susceptibility; 
 run; 
 
proc sort data=phd.phdmicro2 out=phd.phdmicro_nodup 
dupout=phd.phdmicrodups nodupkey; 
 by id; 
run;  
 
Proc sort data = phd.phdmicro_nodup; 
 by id; 
 run; 
 
proc freq data = phd.phdmicro_nodup noprint; 
 table id / out=phd.phdmicronodup1__1; 
 run;  
 
 
data phd.phdmicrodups (rename = (susceptibility = suscep)); 
set phd.phdmicrodups; 
run; 
 
*how to sort and merge.; 
PROC SORT Data=phd.phdmicro_nodup; 
   BY id; 
  RUN;  
   
  PROC SORT Data=phd.phdmicrodups; 
   BY id; 
  RUN;  
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  DATA phd.phdmicroremerge; 
   MERGE phd.phdmicro_nodup phd.phdmicrodups; 
   BY id; 
   run; 
*only 7 and 8 duplicates; 
data phd.phdmicroremerge1; 
 set phd.phdmicroremerge; 
 if suscep = "." then delete; 
 run; 
 
*no duplicates - final dataset; 
data phd.phdmicrofinal; 
 set phd.phdmicroremerge; 
 if SUSCEPTIBILITY = 8 and suscep = 7 then delete; 
 if SUSCEPTIBILITY =7 and suscep = 8 then delete; 
 run; 
 
*(micro masacure is complete); 
 
Proc sort data = phd.phdmicrofinal; 
 by id; 
 run; 
 
proc freq data = phd.phdmicrofinal noprint; 
 table id / out=phd.phdmicrofinal1__1; 
 run;  
 
*Descriptive stats for just micro; 
proc freq data=phd.phdmicrofinal; 
 tables susceptibility*microbial_code; 
 run; 
 
proc freq data=phd.phdmicrofinal; 
 tables susceptibility; 
 run; 
 
*large dataset; 
PROC IMPORT OUT= phd.PHDlarge  
            DATAFILE= "C:\Documents and Settings\Suzanne 
Phillips\Desktop\Suzanne_MRSA\emhdipipa_flag_icu_sep1.txt"  
            DBMS=DLM REPLACE; 
     DELIMITER='7C'x;  
     GETNAMES=YES; 
     DATAROW=2; 
  RUN; 
 
data phd.phdlarge1; 
 set phd.phdlarge; 
 admit= INPUT(ADMITTED_DT_TM, DATE9.); 
 discharge= INPUT(DISCHARGED_DT_TM,DATE9.); 
 tolab= INPUT(MICRO_LAB_RECEIVED_DT_TM, DATE9.); 
 LOS_total= discharge- admit; 
 Pre_infection_LOS = tolab- admit; 
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 Post_infection_LOS = discharge- tolab; 
 Format admitdischargetolabdate9.; 
 format id comma32.; 
run; 
 
Proc sort data = phd.phdlarge1; 
 by id; 
 run; 
 
proc freq data = phd.phdlarge1 noprint; 
 table id / out=phd.phdlarge1__1; 
 run;  
* represents 6750 patients; 
 
/* exclude if pre infection LOS < 2 days. */ 
 
data phd.phdlarge2; 
 set phd.phdlarge1; 
 if pre_infection_LOS >=2; 
run; 
  
 
Proc sort data = phd.phdlarge2; 
 by id; 
 run; 
 
proc freq data = phd.phdlarge2 noprint; 
 table id / out=phd.phdlarge2__1; 
 run;  
 
* this dataset has 3,313 obs; 
 
 
*an aside, pre-infection LOS > 2 n=165,918 ; 
data phd.phdlarge2_1; 
 set phd.phdlarge1; 
 if pre_infection_LOS < 2; 
run; 
 
proc sort data=phd.phdlarge2_2 out=phd.phdlarge2_4 noduprecs; 
by id pre_infection_LOS; 
run; 
 
data phd.phdlarge2_4firstobs phd.dupobs2_4; 
set phd.phdlarge2_4; 
by id; 
if first.id then output phd.phdlarge2_4firstobs; 
else output phd.dupobs2_4; 
run; 
 
proc freq data= phd.phdlarge2_4firstobs; 
 tables ad_source; 
 run; 
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/*After excluding these observations, n= 249,449*/ 
 
*phd.phdlarge3 has 249,449 obs; 
/*Remove duplicate observations */ 
 
proc sort data=phd.phdlarge3 out=phd.phdlarge4 noduprecs; 
by id pre_infection_LOS; 
run; 
 
*phd.phdlarge4 had 5799 obs but there are still some dup where multiple 
cultures were taken in the same admission; 
data phd.phdlargefirstobs phd.dupobs; 
set phd.phdlarge4; 
by id; 
if first.id then output phd.phdlargefirstobs; 
else output phd.dupobs; 
run; 
 
*phd.phdlargefirstobs has 3313 obs; 
 
Proc sort data = phd.phdlargefirstobs; 
 by id; 
 run; 
 
proc freq data = phd.phdlargefirstobs; 
 table id / out=phd.charlson_1; 
 run; 
 
 
 
*Descriptive Statistics; 
 
*large dataset hospitals by year; 
data phd.phdlarge3_1; 
 set phd.phdlarge3; 
format tolabyear4.; 
run; 
 
proc sort data=phd.phdlarge3_1 out=phd.phdlarge3_2; 
by into_microlab_date; 
run; 
 
proc freq data=phd.phdlarge3_2; 
 tables hospital; 
 by into_microlab_date;  
run; 
 
*smaller dataset hospital by year; 
data phd.phdlarge4_1; 
 set phd.phdlarge4; 
format tolabyear4.; 
run; 
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proc sort data=phd.phdlarge4_1 out=phd.phdlarge4_2; 
by into_microlab_date; 
run; 
 
proc freq data=phd.phdlarge4_2; 
 tables hospital; 
 by into_microlab_date;  
run; 
 
*final dataset;  
data phd.phdlargefirstobs_1; 
 set phd.phdlargefirstobs; 
format tolabyear4.; 
run; 
 
proc sort data=phd.phdlargefirstobs_1 out=phd.phdlargefirstobs_2; 
by into_microlab_date; 
run; 
 
proc freq data=phd.phdlargefirstobs_2; 
 tables hospital; 
 by into_microlab_date;  
run; 
 
*merge micro and large file; 
 
/*  micro data = phd.phdmicrofinal - 3275 
 descriptive data = phd.phdlargefirstobs - 3313 
 */ 
 
  PROC SORT Data=phd.phdmicrofinal; 
   BY id; 
  RUN;  
   
  PROC SORT Data=phD.phdlargefirstobs; 
   BY id; 
  RUN;  
 
  DATA phd.phd1; 
   MERGE phd.phdmicrofinal phD.phdlargefirstobs; 
   BY id; 
   run; 
 
  /* merged dataset (phd.phd1) contains 4855 obs */ 
 
 data phd.phd2; 
 set phd.phd1; 
 if SUSCEPTIBILITY <7 then delete; 
 if SUSCEPTIBILITY > 9 then delete; 
 run; 
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  /* merged dataset (phd.phd2) missing micro data eliminated contains 
3275 obs */ 
 
 data phd.phd3; 
 set phd.phd2; 
 if Age <18 then delete; 
 run; 
 
 /* merged dataset (phd.phd3) contains 1733 obs */ 
 
*Calculate Charlson score; 
 
data phd.charlson;  
set phd.diagnosis_codes; 
length uniqueid $ 35;   
dx=icd9_diagnosis_code; 
uniqueid = cat (encounterid); 
run; 
 
proc sort data=phd.charlson; 
by encounterid; 
run; 
 
data a b c d e f g h i j k l m n o p q; 
set phd.charlson;  
if ((substr(dx,1,3) >= '531') & (substr(dx,1,3) <= '534')) then output 
a; 
if substr(dx,1,4) in ('2504','2505','2506','2507') then output b; 
if ((substr(dx,1,3) >= '196') & (substr(dx,1,3) <= '199')) then output 
c; 
if substr(dx,1,3) in ('410','412') then output d; 
if substr(dx,1,3) in ('428') or substr(dx,1,4) in 
('4254','4255','4257','4258','4259') or substr(dx,1,5) in 
('39891','40201','40211','40291','40401','40403','40411','40413','40491
','40493') then output e;            
if substr(dx,1,3) in ('441','440') or substr(dx,1,4) in 
('4439','V434','0930','4373','4431','4432','4438','4471','5571','5579')
then output f; 
if substr(dx,1,3) in 
('430','431','432','433','434','435','436','437','438') or 
substr(dx,1,5)='36234' then output g; 
if substr(dx,1,3)='290' or substr(dx,1,4) in ('2941','3312') then 
output h; 
if substr(dx,1,3) in 
('490','491','492','493','494','495','496','500','501','502','503','504
','505') or substr(dx,1,4) in 
('5064','4168','4169','5064','5081','5088') then output i; 
if substr(dx,1,4) in 
('4465','7100','7102','7103','7101','7104','7140','7141','7142','7148') 
or substr(dx,1,3)='725' or substr(dx,1,5)='71481' then output j; 
if substr(dx,1,4) in ('0706','0709','5733','5734','5738','5739','V427') 
or substr(dx,1,5) in ('07022','07023','07032','07033','07044','07054') 
or substr(dx,1,3) in ('570','571') then output k; 
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if substr(dx,1,4) in ('2500','2501','2502','2503','2508','2509') then 
output l; 
if substr(dx,1,3) in ('342','343') or substr(dx,1,4) in 
('3341','3440','3441','3442','3443','3444','3445','3446','3449') then 
output m; 
if substr(dx,1,3) in ('582','585','586','V56') or substr(dx,1,4) in 
('5830','5831','5832','5834','5836','5837','5880','V420','V451') or 
substr(dx,1,5) in 
('40301','40311','40391','40402','40403','40412','40413','40492','40493
') then output n; 
if substr(dx,1,3) in 
('140','141','142','143','144','145','146','147','148','149','150','151
','152','153','154','155','156','157','158','159','160','161','162','16
3','164','165','166','167','168','169','170','171','172','174','175','1
76','177','178','179','180','181','182','183','184','185','186','187','
188','189','190','191','192','193','194','195','200','201','202','203',
'204','205','206','207','208') or substr(dx,1,4)='2386' then output o; 
if substr(dx,1,4) in ('5722','5723','5724','5728','4560','4561','4562') 
then output p; 
if substr(dx,1,3) in ('042','043','044') then output q; 
run; 
 
proc freq data=a noprint; 
table uniqueid / out=afreq; 
proc freq data=b noprint; 
table uniqueid / out=bfreq; 
proc freq data=c noprint; 
table uniqueid / out=cfreq; 
run; 
proc freq data=d noprint; 
table uniqueid / out=dfreq; 
run; 
proc freq data=e noprint; 
table uniqueid / out=efreq; 
run; 
proc freq data=f noprint; 
table uniqueid / out=ffreq; 
run; 
proc freq data=g noprint; 
table uniqueid / out=gfreq; 
run; 
proc freq data=h noprint; 
table uniqueid / out=hfreq; 
run; 
proc freq data=i noprint; 
table uniqueid / out=ifreq; 
run; 
proc freq data=j noprint; 
table uniqueid / out=jfreq; 
run; 
proc freq data=k noprint; 
table uniqueid / out=kfreq; 
run; 
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proc freq data=l noprint; 
table uniqueid / out=lfreq; 
run; 
proc freq data=m noprint; 
table uniqueid / out=mfreq; 
run; 
proc freq data=n noprint; 
table uniqueid / out=nfreq; 
run; 
proc freq data=o noprint; 
table uniqueid / out=ofreq; 
run; 
proc freq data=p noprint; 
table uniqueid / out=pfreq; 
run; 
proc freq data=q noprint; 
table uniqueid / out=qfreq; 
run; 
 
data phd.ulcer; 
set afreq; 
ulcer = 1; 
drop count percent; 
data phd.dmorgan; 
set bfreq; 
dmodamage = 2; 
drop count percent; 
data phd.mtumor; 
set cfreq; 
mtumor = 6; 
drop count percent; 
run; 
data phd.myocard; 
set dfreq; 
myocard = 1; 
drop count percent; 
run; 
data phd.chf; 
set efreq; 
chf = 1; 
drop count percent; 
run; 
data phd.pvd; 
set ffreq; 
pvd = 1; 
drop count percent; 
run; 
data phd.cerebro; 
set gfreq; 
cerebro = 1; 
drop count percent; 
run; 
data phd.dementia; 
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set hfreq; 
dementia = 1; 
drop count percent; 
run; 
data phd.copd; 
set ifreq; 
copd = 1; 
drop count percent; 
run; 
data phd.rheum; 
set jfreq; 
rheum = 1; 
drop count percent; 
run; 
data phd.mildliver; 
set kfreq; 
mildliver = 1; 
drop count percent; 
run; 
data phd.dbnocomp; 
set lfreq; 
dbnocomp = 1; 
drop count percent; 
run; 
data phd.hemiplegia; 
set mfreq; 
mtumor = 6; 
drop count percent; 
run; 
data phd.renal; 
set nfreq; 
renal = 2; 
drop count percent; 
run; 
data phd.cancer; 
set ofreq; 
cancer = 2; 
drop count percent; 
run; 
data phd.msliver; 
set pfreq; 
msliver = 3; 
drop count percent; 
run; 
data phd.hiv; 
set qfreq; 
hiv = 6; 
drop count percent; 
run; 
 
data phd.phd3beforecharlson; 
set phd.phd3; 
length uniqueid $ 35; 
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uniqueid = cat (id); 
run; 
 
proc sort data=phd.phd3beforecharlson; 
by uniqueid; 
run; 
 
 
data phd.phd3_aftercharlson;; 
merge phd.phd3beforecharlson phd.ulcer phd.dmorgan phd.mtumor  
phd.myocard phd.chf phd.pvd phd.cerebro phd.dementia phd.copd phd.rheum 
phd.mildliver phd.dbnocomp phd.hemiplegia phd.renal 
phd.cancer phd.msliver phd.hiv; 
by uniqueid; 
if ulcer = . then ulcer = 0; 
if dmodamage = . then dmodamage = 0; 
if mtumor = . then mtumor = 0; 
if myocard = . then myocard= 0; 
if chf = . then chf=0; 
if pvd = . then pvd=0; 
if cerebro = . then cerebro=0; 
if dementia = . then dementia = 0; 
if copd = . then copd = 0; 
if rheum = . then rheum = 0; 
if dbnocomp = . then dbnocomp = 0; 
if hemiplegia = . then hemiplegia = 0; 
if renal = . then renal = 0; 
if cancer = . then cancer = 0; 
if msliver = . then msliver = 0; 
if mildliver = . then mildliver = 0; 
if hiv = . then hiv = 0; 
 
charlson = sum(ulcer, dmodamage, mtumor, myocard, chf, pvd, cerebro, 
dementia, copd, rheum, dbnocomp, hemiplegia, renal, cancer, msliver, 
mildliver, hiv); 
run; 
 
 data phd.mergedwithcharlson; 
 set phd.phd3_aftercharlson; 
 if id = . then delete; 
 run; 
 
 
proc univariate data = phd.mergedwithcharlson; 
class charlson; 
var charlson; 
run; 
 
 
*add in DRG relative weights; 
 
PROC IMPORT OUT= WORK.DRG  
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            DATAFILE= "C:\Documents and Settings\Suzanne Phillips\My 
Doc 
uments\PhD\2006drg_relative_weights.xls"  
            DBMS=EXCEL REPLACE; 
     SHEET="drgimport1$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
RUN; 
 
data phd.drg; 
 set drg; 
 run; 
 
 data phd.mergedwithcharlson1; 
  set phd.mergedwithcharlson; 
 if total_charges <=0 then delete; 
 drg = drg_id; 
 if drg <=0 then delete; 
run; 
 
*data set now contains 1088 obs; 
 
*add drg weights (phd.drg) into dataset (phd.mergedwithcharlson); 
 
  PROC SORT Data= phd.drg; 
   BY drg; 
  RUN;  
   
  PROC SORT Data=phd.mergedwithcharlson1; 
   BY drg; 
  RUN;  
 
  DATA phd.drg_charlson; 
   MERGE phd.drg phd.mergedwithcharlson1; 
   BY drg; 
   run; 
 
  data phd.drg_charlson_1088; 
  set phd.drg_charlson_1088; 
 if id = . then delete; 
 run; 
 
  data phd.drg_charlson_drg_weight; 
  set phd.drg_charlson_1088; 
 if weights = . then delete; 
 if weights <= 0 then delete; 
 run; 
 
*dataset contains 966 pts; 
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*must adjust for inflation; 
 
data phd.drg_charlson1; 
 set phd.drg_charlson_drg_weight; 
 discharge_year = year (discharge_date); 
 if discharge_year = 2000 then cpi=1.475; 
 if discharge_year = 2001 then cpi=1.384; 
 if discharge_year = 2002 then cpi=1.273; 
 if discharge_year = 2003 then cpi=1.186; 
 if discharge_year = 2004 then cpi=1.196; 
 if discharge_year = 2005 then cpi=1.064; 
 if discharge_year = 2006 then cpi=1; 
 charge = (total_charges * cpi);  
run; 
 
*re-visit LOS delete if pre-infection LOS is < 62 days; 
 
data phd.drg_charlson2; 
 set phd.drg_charlson1; 
 if Pre_infection_LOS >62 then delete; 
 run; 
 
 *tweak the dataset - look for low cost payers; 
data phd.drg_charlson3; 
 set phd.drg_charlson2; 
 if post_infection_los < 0 then delete; 
 run; 
 
*sample size = 948 b/c 9 people has post-infection LOS < 0; 
 
data phd.drg_charlson4; 
 set phd.drg_charlson3; 
 if charge < 11896 and LOS_total>= 9 then delete; 
 run; 
 
*sample size = 930; 
libname phdfinal 'C:\Documents and Settings\Suzanne Phillips\My 
Documents\PhD'; 
run; 
 
data phdfinal.final; 
 set phd.drg_charlson4; 
run; 
 
data phdfinal.final_1; 
 set phdfinal.final; 
if ad_source = 1 then admission_source = 1; 
if ad_source = 2 then admission_source = 1; 
if ad_source = 3 then admission_source = 1; 
if ad_source = 4 then admission_source = 2; 
if ad_source = 5 then admission_source = 2; 
if ad_source = 6 then admission_source = 2; 
if ad_source = 10 then admission_source = 2; 
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if ad_source = 7 then admission_source = 7; 
if ad_source = 8 then admission_source = 8; 
if ad_source = 17 then admission_source = 3; 
if ad_source = 20 then admission_source = 3; 
if ad_source = 9 then admission_source = 3; 
if payer= 14 then payer = 1; 
 if payer= 15 then payer = 1; 
 if payer= 16 then payer = 1; 
 if payer= 18 then payer = 1; 
 if payer= 13 then payer = 1; 
 if payer= 21 then payer = 1; 
 if payer=1 then payer = 1; 
 if payer=2 then payer = 1; 
 if payer=4 then payer = 1; 
 if payer=17 then payer = 2; 
 if payer=22 then payer = 3; 
 if payer=20 then payer = 3; 
 if payer=23 then payer = 3; 
 if payer=10 then payer = 4; 
 if payer=11 then payer = 4; 
 if payer=6 then payer = 5; 
 if payer=7 then payer = 5; 
If DISCHARGE_CODE= 1 then discharge =1; 
If DISCHARGE_CODE= 8 then discharge =1; 
If DISCHARGE_CODE= 6 then discharge =1; 
If DISCHARGE_CODE= 2 then discharge =2; 
If DISCHARGE_CODE= 3 then discharge =2; 
If DISCHARGE_CODE= 4 then discharge =2; 
If DISCHARGE_CODE= 5 then discharge =2; 
If DISCHARGE_CODE= 22 then discharge =2; 
If DISCHARGE_CODE= 23 then discharge =2; 
If DISCHARGE_CODE= 11 then discharge =3; 
If DISCHARGE_CODE= 7 then discharge =4; 
If DISCHARGE_CODE= 12 then discharge =4; 
If DISCHARGE_CODE= 15 then discharge =4; 
If DISCHARGE_CODE= 18 then discharge =5; 
If DISCHARGE_CODE= 25 then discharge =5; 
If DISCHARGE_CODE= 13 then discharge =6; 
If DISCHARGE_CODE= 14 then discharge =6; 
If DISCHARGE_CODE= 1 then discharge_status =1; 
If DISCHARGE_CODE= 8 then discharge_status =1; 
If DISCHARGE_CODE= 6 then discharge_status =1; 
If DISCHARGE_CODE= 2 then discharge_status =1; 
If DISCHARGE_CODE= 3 then discharge_status =1; 
If DISCHARGE_CODE= 4 then discharge_status =1; 
If DISCHARGE_CODE= 23 then discharge_status =1; 
If DISCHARGE_CODE= 22 then discharge_status =1; 
If DISCHARGE_CODE= 5 then discharge_status =1; 
If DISCHARGE_CODE= 11 then discharge_status =0; 
If DISCHARGE_CODE= 7 then discharge_status =1; 
If DISCHARGE_CODE= 12 then discharge_status =1; 
If DISCHARGE_CODE= 15 then discharge_status =1; 
If DISCHARGE_CODE= 18 then discharge_status =2; 
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If DISCHARGE_CODE= 25 then discharge_status =2; 
If DISCHARGE_CODE= 13 then discharge_status =1; 
If DISCHARGE_CODE= 14 then discharge_status =1; 
If discharge_status =0 then mortality = 0; 
If discharge_status =1 then mortality = 1; 
run; 
* Admission Source 1=referral, 2=transfer, 7=ER, 8=Court/Law 
enforcement, 3=NA; 
* Payer 1= Insured, 2=self pay, 3=N/A, 4=Medicaid, 5=Medicare; 
*Discharge home=1, transfer = 2, expired =3, other = 4, N/A = 5, 
Hospice = 6; 
*Discharge status alive =1, dead = 0 n/a=2; 
 
  
 
*categorical data frequency table; 
 
proc freq data=phdfinal.final_1; 
 tables susceptibility * gender / chisq; 
 run; 
 
proc freq data=phdfinal.final_1; 
 tables admission_source * susceptibility / chisq; 
 run; 
 
proc freq data=phdfinal.final_1; 
 tables discharge * susceptibility  / chisq; 
 run; 
 
proc freq data=phdfinal.final_1; 
 tables discharge_status * susceptibility  / chisq; 
 run; 
 
proc freq data=phdfinal.final_1; 
 tables payer * susceptibility / chisq; 
 run; 
 
*continuous data analysis; 
proc npar1way data=phdfinal.final_1 wilcoxon; 
 class susceptibility; 
 var age; 
run; 
 
proc npar1way data=phdfinal.final_1 wilcoxon; 
 class susceptibility; 
 var charlson; 
run; 
 
proc npar1way data=phdfinal.final_1; 
 class susceptibility; 
 var weights; 
run; 
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proc npar1way data=phdfinal.final_1; 
 class susceptibility; 
 var pre_infection_LOS; 
run; 
 
proc npar1way data=phdfinal.final_1; 
 class susceptibility; 
 var post_infection_LOS; 
run; 
 
proc npar1way data=phdfinal.final_1; 
 class susceptibility; 
 var total_LOS; 
run; 
 
proc npar1way data=phdfinal.final_1; 
 class susceptibility; 
 var charge; 
 run; 
 
*repeated measures ANOVA - interested in mean charge but must take into 
account suseptibility status & hospital #; 
 
Proc sort data = phdfinal.final_1; 
 by hospital susceptibility; 
 run; 
 
proc transpose data=phdfinal.final_1 
    let 
    label  = discharge_year 
    name = charge 
    out = phdfinal.final_1a; 
by hospital susceptibility; 
id discharge_year; 
var charge; 
run; 
 
ODS graphics on; 
proc glm data = phdfinal.final_1a; 
 class susceptibility hospital; 
 model _2000 _2001 _2002 _2003 _2004 _2005 _2006 = susceptibility 
hospital; 
 repeated year 7 / printe summary; 
 run; 
 
proc means data= phdfinal.final_1a; 
 by susceptibility; 
 var _2000 _2001 _2002 _2003 _2004 _2005 _2006; 
 run; 
 
proc plot data = phdfinal.final_1; 
 by descending susceptibility; 
 plot charge*discharge_year; 
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run; 
 
Proc sort data = phdfinal.final_1; 
 by discharge_year susceptibility; 
 run; 
 
  proc gplot data= phdfinal.final_1; 
     PLOT charge*discharge_year=susceptibility ; 
RUN;  
 
symbol1 v=triangle c = r; 
proc boxplot data=phdfinal.final_1;  
plot charge*discharge_year /  
  boxstyle=schematic 
  vaxis=axis2  
 cboxes   = bl 
 clipfactor = 2;  
insetgroup nhigh mean/ header = 'Outliers per year'; 
 label charge='Total Charge in dollars';   
label discharge_year='Discharge Year';  
run;  
 
 
*propensity score - hospital size, hospital teaching status, 
urban/rural status; 
 
data phdfinal.final_1a; 
 set phdfinal.final_1; 
 if susceptibility = 7 then susceptibility = 1; 
 if susceptibility = 8 then susceptibility = 0; 
 run; 
 
 
proc logistic data = phdfinal.final_1a descending; 
 class bedteach urban_rural_status_ind; 
 model susceptibility = bed teach urban_rural/ lackfit corrb; 
 OUTPUT OUT= phdfinal.final_2 prob=prob; 
 RUN; 
 
 
proc univariate data=phdfinal.final_2 plot; 
 var prob; 
 run; 
 
Proc sort data = phdfinal.final_2; 
 by susceptibility; 
 run; 
 
symbol1 v=triangle c = r; 
proc boxplot data=phdfinal.final_2;  
plot prob*susceptibility /  
  boxstyle=skeletal 
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  vaxis=axis2  
 cboxes   = bl; 
 label prob ='Propensity Score';   
label susceptibility ='Susceptibility';  
run;  
 
proc rank data=phdfinal.final_2 groups = 5 out = phdfinal.rank; 
 ranks ranks; 
 var prob; 
 run; 
 
data phdfinal.final_2a; 
 set phdfinal.rank; 
 quintile = ranks + 1; 
 if quintile = 2 then ps2 =1; else ps2 = 0; 
 if quintile = 3 then ps3 =1; else ps3 = 0; 
 if quintile = 4 then ps4 =1; else ps4 = 0; 
 if quintile = 5 then ps5 =1; else ps5 = 0; 
 run; 
 
proc freq data=phdfinal.final_2a; 
 tables quintile*susceptibility; 
 run; 
 
proc univariate data=phdfinal.final_2a plot; 
 var prob quintile; 
 run; 
 
*propensity score = prob; 
 
*Univariate analysis (obj 2)each variable by charge; 
proc genmod data = phdfinal.final_2a; 
 model charge = susceptibility age / dist=gamma link=log obstats; 
 run; 
 
proc genmod data = phdfinal.final_2a; 
 model charge = susceptibility weights / dist=gamma link=log 
obstats; 
 run; 
 
proc genmod data = phdfinal.final_2a; 
 model charge = susceptibility charlson / dist=gamma link=log 
obstats; 
 run; 
 
proc genmod data = phdfinal.final_2a; 
 model charge = susceptibility pre_infection_LOS / dist=gamma 
link=log obstats; 
 run; 
 
proc genmod data = phdfinal.final_2a; 
 model charge = susceptibility mortality / dist=gamma link=log 
obstats; 
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 run; 
 
proc genmod data = phdfinal.final_2a; 
 class gender; 
 model charge = susceptibility gender / dist=gamma link=log 
obstats; 
 run; 
 
 
*multivarable model - obj 2; 
proc genmod data = phdfinal.final_2a; 
 class gender; 
 model charge = susceptibility gender prob weights charlson age 
pre_infection_LOS mortality / dist=gamma link=log obstats; 
 run; 
 
*remove age; 
proc genmod data = phdfinal.final_2; 
 class gender; 
 model charge = susceptibility gender prob weights charlson 
pre_infection_LOS mortality / dist=gamma link=log obstats; 
 run; 
 
*test homogeneity of slope assumption; 
data phdfinal.final_3; 
set phdfinal.final_2a; 
if GENDER = 'Female' then sex = '0'; 
Else sex = '1'; 
gender1=input(sex,comma4.); 
X3 = susceptibility * gender1; 
x2 = susceptibility * weights; 
x1 = susceptibility * charlson;  
x4 = susceptibility * pre_infection_LOS; 
x5 = susceptibility * mortality; 
X6 = weights*pre_infection_LOS; 
X7 = gender1 * charlson; 
X8 = weights * charlson; 
X9 = weights*mortality; 
X10 = weights* gender1; 
X11 = gender1 * mortality; 
X12 = gender1 * pre_infection_LOS; 
X13 = charlson * pre_infection_LOS; 
X14 = charlson*mortality; 
X15 = pre_infection_LOS * mortality;  
run;  
 
 
 
proc genmod data = phdfinal.final_3; 
 class gender; 
 model charge = susceptibility gender prob weights charlson 
pre_infection_LOS mortality x1 x2 x3 x4 x5 
/ dist=gamma link=log type1; 
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 run; 
 
 
*2-way interactions; 
proc genmod data = phdfinal.final_3; 
 model charge = susceptibility gender1 prob weights charlson 
pre_infection_LOS mortality x1 x2 x6 x7 x8 x9 
 x10 x11 x12 x13 x14 x15/ dist=gamma link=log type1; 
 run; 
 
*final model obj 2; 
 
 data phdfinal.final_3a; 
 set phdfinal.final_3; 
 if susceptibility = 7 then susceptibility = 1; 
 if susceptibility = 8 then susceptibility = 0; 
 run; 
 
proc genmod data = phdfinal.final_3a; 
 model charge = susceptibility gender1 prob weights charlson 
pre_infection_LOS mortality x1 x2 x6 x7  
 / dist=gamma link=log covb corrb obstats type1 type3 waldci; 
 output out=phdfinal.gencook resraw=resraw reschi=reschi 
stdreschi=stdreschi pred=pred resdev=resdev; 
 run; 
 
proc univariate data = phdfinal.gencook; 
var pred; 
run; 
 
proc sort data = phdfinal.gencook; 
by susceptibility; 
run; 
 
proc univariate data = phdfinal.gencook; 
by susceptibility; 
var pred; 
run; 
 
*reschi are pearson residuals; 
 
proc plot data=phdfinal.gencook; 
plot charge*pred; 
plot stdreschi * pred; 
plot resraw * pred; 
plot reschi * pred; 
plot resdev * pred; 
run; 
 
*influential diagnostics ; 
 
ods output covb=covb parameterestimates=parameterestimates;  
proc genmod data=phdfinal.final_3; 
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 model charge = susceptibility gender1 prob weights charlson 
pre_infection_LOS mortality x1 x2 x6 x7  
 / dist=gamma link=log r covb corrb obstats type1 type3 waldci; 
 output out=phdfinal.gencook2 resraw=resraw reschi=reschi 
stdreschi=stdreschi pred=pred; 
run; 
 
proc iml; 
use phdfinal.gencook2; 
read all var {susceptibility gender1 prob weights charlson 
pre_infection_LOS mortality x1 x2 x6 x7} into x; 
read all var {charge} into y; 
read all var {resraw} into resraw; 
read all var {reschi} into reschi; 
read all var {stdreschi} into stdreschi; 
 
use covb; 
read all var {prm1 prm2 prm3 prm4 prm5 prm6 prm7 prm8 prm9 prm10 prm11 
prm12 scale} into covb; 
 
use parameterestimates; 
read all var {estimate} into estimate; 
 
p=ncol(x); 
n=nrow(x); 
 
/*scale = estimate[p+1.]##2;*/ 
scale = estimate[p+2.]##2; 
 
rr=(reschi/stdreschi)##2; 
invrr = 1/rr; 
 
stddev=sqrt(vecdiag(covb)); 
 
add=j(n,1,1); 
newx=add||x||add; 
/*tx = t(x);*/ 
tx = t(newx); 
 
lev = J(n,1.1)- rr/scale; 
D=(1/p)#(lev/(1-lev))#(stdreschi##2); 
dfbeta = covb * tx * diag(invRR#resraw); 
dfbetas = dfbeta#(stddev##-1); 
 
print lev; 
print D; 
print dfbeta; 
print dfbetas; 
run; 
 
proc univariate data=phdfinal.gencook2; 
var pred; 
 run; 
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proc univariate data=phdfinal.gencook2; 
by susceptibility; 
var pred; 
 run; 
 
 
*removed if dev residuals > 3 - 5 obs were deleted (n=925); 
data phdfinal.gencook2a; 
 set phdfinal.gencook; 
if resdev > 3 then delete; 
run; 
 
*rerun analysis; 
proc genmod data = phdfinal.gencook2a; 
 model charge = susceptibility age / dist=gamma link=log obstats; 
 run; 
 
proc genmod data = phdfinal.gencook2a; 
 model charge = susceptibility weights / dist=gamma link=log 
obstats; 
 run; 
 
proc genmod data = phdfinal.gencook2a; 
 model charge = susceptibility charlson / dist=gamma link=log 
obstats; 
 run; 
 
proc genmod data = phdfinal.gencook2a; 
 model charge = susceptibility pre_infection_LOS / dist=gamma 
link=log obstats; 
 run; 
 
proc genmod data = phdfinal.gencook2a; 
 model charge = susceptibility mortality / dist=gamma link=log 
obstats; 
 run; 
 
proc genmod data = phdfinal.gencook2a; 
 class gender; 
 model charge = susceptibility gender / dist=gamma link=log 
obstats; 
 run; 
 
 
*rerun multivarable model - obj 2; 
proc genmod data = phdfinal.gencook2a; 
 model charge = susceptibility prob weights charlson 
pre_infection_LOS mortality / dist=gamma link=log obstats; 
 run; 
 
*test homogeneity of slope assumption; 
data phdfinal.gencook2aa; 
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set phdfinal.gencook2a; 
x2 = susceptibility * weights; 
x1 = susceptibility * charlson;  
x4 = susceptibility * pre_infection_LOS; 
x5 = susceptibility * mortality; 
X6 = weights*pre_infection_LOS; 
X8 = weights * charlson; 
X9 = weights*mortality; 
X10 = weights* gender1; 
X13 = charlson * pre_infection_LOS; 
X14 = charlson*mortality; 
X15 = pre_infection_LOS * mortality;  
run;  
 
proc genmod data = phdfinal.gencook2aa; 
 class gender; 
 model charge = susceptibility gender prob weights charlson 
pre_infection_LOS mortality x1 x2 x4 x5 
/ dist=gamma link=log type1; 
 run; 
 
 
*2-way interactions; 
proc genmod data = phdfinal.gencook2aa; 
 model charge = susceptibility gender1 prob weights charlson 
pre_infection_LOS mortality x1 x6 x8 x9 
 x10 x13 x14 x15/ dist=gamma link=log type1; 
 run; 
 
*keep only x1 and x6; 
 
*final model obj 2; 
 
 data phdfinal.gencook2aaa; 
 set phdfinal.gencook2aa; 
 if susceptibility = 7 then susceptibility = 1; 
 if susceptibility = 8 then susceptibility = 0; 
 run; 
 
proc genmod data = phdfinal.gencook2aaa; 
 model charge = susceptibility prob weights charlson 
pre_infection_LOS mortality x1 x6  
 / dist=gamma link=log covb corrb obstats type1 type3 waldci; 
 output out=phdfinal.gencook resraw=resraw reschi=reschi 
stdreschi=stdreschi pred=pred resdev=resdev; 
 run; 
 
proc univariate data = phdfinal.gencook2aaa; 
var pred; 
run; 
 
proc sort data = phdfinal.gencook2aaa;; 
by susceptibility; 
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run; 
 
proc univariate data = phdfinal.gencook2aaa; 
by susceptibility; 
var pred; 
run; 
 
*rerun analysis with propensity scores as quintiles; 
proc genmod data = phdfinal.gencook2aaa; 
 model charge = susceptibility ps2 ps3 ps4 ps5 weights charlson 
pre_infection_LOS mortality x1 x6  
 / dist=gamma link=log covb corrb obstats type1 type3 waldci; 
 output out=phdfinal.gencook1 resraw=resraw reschi=reschi 
stdreschi=stdreschi pred=pred resdev=resdev; 
 run; 
 
 
*Univariate analysis (obj 3)each variable by post-infection LOS; 
 
*propensity score = prob; 
 
*Univariate analysis (obj 3)each variable by charge; 
proc genmod data = phdfinal.gencook2aaa; 
 model post_infection_LOS = susceptibility age / dist=gamma 
link=log obstats; 
 run; 
 
proc genmod data = phdfinal.gencook2aaa; 
 model post_infection_LOS = susceptibility weights / dist=gamma 
link=log obstats; 
 run; 
 
proc genmod data = phdfinal.gencook2aaa; 
 model post_infection_LOS = susceptibility charlson / dist=gamma 
link=log obstats; 
 run; 
 
proc genmod data = phdfinal.gencook2aaa; 
 model post_infection_LOS = susceptibility pre_infection_LOS / 
dist=gamma link=log obstats; 
 run; 
 
proc genmod data = phdfinal.gencook2aaa; 
 model post_infection_LOS = susceptibility mortality / dist=gamma 
link=log obstats; 
 run; 
 
proc genmod data = phdfinal.gencook2aaa; 
 class gender; 
 model post_infection_LOS = susceptibility gender / dist=gamma 
link=log obstats; 
 run; 
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*multivarable model - obj 3; 
proc genmod data = phdfinal.gencook2aaa; 
 model post_infection_LOS = susceptibility prob weights charlson 
age pre_infection_LOS mortality / dist=gamma link=log obstats; 
 run; 
 
*remove age; 
proc genmod data = phdfinal.gencook2aaa; 
  model post_infection_LOS = susceptibility prob weights 
charlson pre_infection_LOS mortality / dist=gamma link=log obstats; 
 run; 
 
*test homogeneity of slope assumption; 
data phdfinal.gencook2aaaa; 
set phdfinal.gencook2aaa; 
 
x2 = susceptibility * weights; 
x1 = susceptibility * charlson;  
x4 = susceptibility * pre_infection_LOS; 
x5 = susceptibility * mortality; 
X6 = weights*pre_infection_LOS; 
X8 = weights * charlson; 
X9 = weights*mortality; 
X13 = charlson * pre_infection_LOS; 
X14 = charlson*mortality; 
X15 = pre_infection_LOS * mortality;  
run;  
 
proc genmod data = phdfinal.gencook2aaaa; 
 model post_infection_LOS = susceptibility prob weights charlson 
pre_infection_LOS mortality x4 x2 x1 x5 
/ dist=gamma link=log type1; 
 run; 
 
 
*2-way interactions; 
proc genmod data = phdfinal.gencook2aaaa; 
 model post_infection_LOS = susceptibility prob weights charlson 
pre_infection_LOS mortality x4 x13 x9 
 x14 x8 x15/ dist=gamma link=log type1; 
 run; 
 
*final model obj 3; 
proc genmod data = phdfinal.gencook2aaaa; 
 model post_infection_LOS = susceptibility  prob weights charlson 
pre_infection_LOS mortality x4 x13  
 / dist=gamma link=log covb corrb obstats type1 type3 waldci; 
 output out=phdfinal.LOSgencookaa resraw=resraw reschi=reschi 
stdreschi=stdreschi pred=pred resdev=resdev; 
 run; 
 
proc univariate data = phdfinal.LOSgencookaa; 
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var pred2; 
run; 
 
proc sort data = phdfinal.LOSgencook; 
by susceptibility; 
run; 
 
proc univariate data = phdfinal.LOSgencook; 
by susceptibility; 
var pred2; 
run; 
 
 
*path analysis; 
proc calis data=phdfinal.gencook2aaaac corr residual pall toteff; 
var susceptibility pre_infection_LOS Post_infection_LOS charge; 
lineqs 
Post_infection_LOS = b32 pre_infection_LOS + b31 susceptibility + e3, 
charge = b43 Post_infection_LOS + b42  pre_infection_LOS + e4; 
std 
susceptibility = var_susc, 
pre_infection_LOS = var_preLOS, 
e3 = var_e3, 
e4 = var_e4; 
cov 
susceptibility pre_infection_LOS = c_spre; 
run; 
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